BEATING CANCER IS IN OUR BLOOD
# TABLE OF CONTENTS

**PRESIDENT & CHAIRMAN’S MESSAGE**  
3

**SECTION 1**  
**OUR IMPACT AT A GLANCE**  
4

**SECTION 2**  
**OUR MISSION:**  
6

**RESEARCH**  
7

- INVESTING IN GROUNDBREAKING CANCER RESEARCH
- DRIVING IMPACT BEYOND BLOOD CANCERS
- BRINGING PRECISION MEDICINE TO AML PATIENTS
- ADVANCING NEW LIFESAVING THERAPIES

**EDUCATION & SUPPORT**  
33

**POLICY & ADVOCACY**  
41

**SECTION 3**  
**VOLUNTEERS IMPACT OUR MISSION**  
48

**SECTION 4**  
**FUNDRAISING CAMPAIGNS**  
49

**SECTION 5**  
**PARTNERSHIPS**  
53

**SECTION 6**  
**FINANCIALS**  
56

**SECTION 7**  
**ACKNOWLEDGMENTS**  
73
President & Chairman’s Message

Every three minutes, someone in the United States is diagnosed with a blood cancer, including leukemia, lymphoma or myeloma. Cancer is a tough opponent, but we at The Leukemia & Lymphoma Society (LLS) are tougher.

Our track record in accelerating lifesaving treatments is unparalleled, and we champion the most pioneering research to fuel our attack against cancer. We are laser-focused on cures, and we’re relentless in supporting patients and their families throughout their cancer experience to ensure they have access to care. Our work is advancing breakthroughs for more than 1.3 million Americans living with or in remission from a blood cancer, and importantly, it is helping patients with other cancers and diseases.

Nearly 70 years of fighting blood cancers has led us to a game changing belief. Beating cancer is in our blood. With your support, we are transforming this powerful belief in finding cures into reality for more patients.

Gratefully,

Louis J. DeGennaro, Ph.D.
President & Chief Executive Officer

Peter Brock
Chairman of the Board
OUR IMPACT AT A GLANCE

Here at LLS, we have a bold vision: a world without blood cancers. The impact that we are making on the lives of patients and their families gives us confidence that we will achieve this goal in our lifetime.

Our incredible progress this year puts us at the forefront of the fight to cure cancer. LLS achieved a record fundraising year, generating almost $450 million in revenue that allowed us to invest even more in our mission and help more patients. Our record success is driving innovation across the cancer landscape. Revolutionary new treatments, originally discovered through blood cancer research, are now being tested in clinical trials for other cancers. Not only is the blood an important starting place to find cures for cancer, but it is in our DNA – it is what we do at LLS every day.

That's why we are the only organization that can say proudly

BEATING CANCER IS IN OUR BLOOD.
THANKS TO YOU, LLS HAS:

RAISED THE BAR FOR PEER-TO-PEER FUNDRAISING
Together, participants across all of our campaigns helped us raise a record-breaking total of more than $250 million. Our powerful Light The Night campaign is now the fifth largest peer-to-peer fundraising program in America.

ENGAGED THE NEXT GENERATION OF PHILANTHROPIC LEADERS
Through LLS’s newest innovation in fundraising, Students of the Year, more than 600 motivated high school student teams raised significant funds for our mission.

ADVANCED NEW TREATMENTS FOR PATIENTS WITH CANCER
LLS helped advance 34 of the 39 blood cancer treatments approved by the U.S. Food and Drug Administration (FDA) since 2017.

FUNDED THE MOST VISIONARY CANCER RESEARCH WORLDWIDE
Our $188 million multi-year research commitment spans the most promising science across all blood cancers, including immunotherapy, genomics and personalized medicine.

EXPANDED CLINICAL TRIAL EDUCATION AND ENROLLMENT
LLS Information Specialists responded to nearly 20,000 inquiries from patients and caregivers, including inquiries about clinical trials. LLS Clinical Trial Support Center (CTSC) nurses provided 562 patients with in-depth clinical trial navigation and support – up 65 percent from 2017.

PROVIDED DIRECT SUPPORT TO PATIENTS IMPACTED BY NATURAL DISASTERS
We committed up to $1 million in aid to support blood cancer patients impacted by Hurricanes Harvey, Irma and Maria and California wildfires.

MADE OUR VOICES HEARD ON BEHALF OF CANCER PATIENTS AND SURVIVORS
More than 100,000 volunteer advocates across the country acted as a powerful voice for cancer patients and survivors to influence change at the state and federal level.

ACHIEVED A MAJOR WIN FOR DEDICATED PEDIATRIC CANCER RESEARCH
Our Office of Public Policy, along with LLS volunteer advocates, sent thousands of letters to help pass into law The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act, the most comprehensive federal childhood cancer legislation ever introduced.
OUR MISSION

At LLS, our mission is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.

As the world’s largest nonprofit dedicated to fighting blood cancers, our work has helped millions impacted by cancer. Though LLS is known for funding groundbreaking research to find better treatments and cures, we do so much more. We provide free information, education and support services for those who are newly diagnosed and those living with their disease. We fight for lifesaving policy changes at the state and federal level to ensure access to quality, affordable, coordinated care.

We are committed to working tirelessly toward our mission every single day, until we find cures.

Dr. Gwen Nichols
Chief Medical Officer
The Leukemia & Lymphoma Society
RESEARCH

Contributing to nearly every advancement in blood cancer treatment in recent decades, LLS is the largest nonprofit funder of cutting-edge blood cancer research to advance cures.

In fact, we have invested more than $1.2 billion in cancer research since we started in 1949, leading to breakthroughs in immunotherapy, genomics and personalized medicine that are improving and saving the lives of patients.

Jessica, Cancer Survivor
INVESTING IN GROUNDBREAKING CANCER RESEARCH

Our robust research portfolio supports the careers of next-generation scientists, advances research in areas of urgent, unmet medical need, and drives forward lifesaving discoveries through impactful collaborations.
Since 1949, The Leukemia & Lymphoma Society (LLS) has invested more than $1.2 billion in cutting-edge cancer research, funding nearly all of today’s most promising treatments and bringing us closer to cures. We support the most outstanding scientists and physicians around the world.

RESEARCH IN NUMBERS

In 2018, we supported more than 235 research grants and 20 Therapy Acceleration Program® (TAP) partnerships, a $188 million multi-year commitment.

This year, LLS dedicated $46 million to support scientific grants, including 87 new grants awarded in 2018 alone to researchers across nine countries, making us the largest nonprofit funder of blood cancer research. We invest in pioneering researchers whose work runs the gamut from basic, laboratory-based science to large-scale clinical trials, and many of our grants sustain their projects over multiple years.

Through TAP, we partner directly with biotechnology companies and renowned academic centers to help accelerate the development of promising therapies. This year, we invested $6.4 million of our 2018 research budget in our TAP program. Now in its eleventh year, TAP is currently supporting 20 partnerships.

While incredible progress has been made, challenges remain. More than one-third of blood cancer patients still do not survive five years after their diagnosis. By funding the most innovative research, we will achieve breakthroughs faster for patients who urgently need them.

SPOTLIGHT ON TAP

In the past year, LLS’s Therapy Acceleration Program® (TAP) achieved an important milestone when three therapies were approved by the U.S. Food and Drug Administration (FDA) to treat blood cancers with high unmet medical need. What’s more, two of these therapies are now approved for use in the European Union – highlighting the global impact that we are making in the fight against cancer.

- **CPX-351 (Vyxeos)***, funded by TAP since 2009, was approved for the treatment of patients with certain types of high-risk acute myeloid leukemia (AML).

- **axicabtagene ciloleucel (Yescarta)**, funded by TAP since 2015, became the first FDA-approved CAR (chimeric antigen receptor) T-cell immunotherapy for patients with certain types of non-Hodgkin lymphoma.

- **tagraxofusp (Elzonris)**, funded by TAP since 2013, became the first FDA-approved treatment for adults and pediatric patients age two or older with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a particularly aggressive and rare disease.
WE ARE ELEVATING THE GAME CHANGING FIELD OF IMMUNOTHERAPY TO NEW HEIGHTS

Recognizing the tremendous potential of immunotherapy, LLS was an early supporter of research in the field and has played a pivotal role in driving its development.

From CAR (chimeric antigen receptor) T-cell immunotherapy and cancer vaccines to monoclonal antibodies, LLS is committed to advancing the next generation of these groundbreaking therapies to improve the lives of patients.

ERIC SMITH, MD, PHD

Eric Smith, MD, PhD, Memorial Sloan Kettering Cancer Center (MSKCC), is focused on optimizing CAR T-cell immunotherapy for myeloma. Despite recent advances, almost all patients experience relapse or treatment resistance. To address this, Dr. Smith is engineering CAR T-cells to attack a protein called BCMA (B-cell maturation antigen), found on the surface of myeloma cells. Dr. Smith is part of a larger initiative at MSKCC under the guidance of Anas Younes, MD, Michel Sadelain MD, PhD and Renier Brentjens, MD, PhD to apply the latest CAR T-cell technology across many different blood cancers.

FORTY SEVEN, INC.

Forty Seven, Inc., a Silicon Valley biotech startup in our TAP portfolio, is working on a promising experimental immunotherapy for patients with some types of lymphoma, acute myeloid leukemia (AML) and solid tumors. The therapy works by disarming a protein that emits a “don’t eat me” signal. Under normal conditions, the cancer cells would evade destruction, but in the presence of an antibody, immune cells ingest and destroy tumor cells. The program grew out of grants funded by LLS at Stanford University.

SHANNON ODA, PhD

Shannon Oda, PhD, Fred Hutchinson Cancer Research Center, is focused on enhancing T-cell immunotherapy for AML by studying how to overcome the obstacles that make some patients resistant to the treatment.

ROBERT ORLOWSKI, MD, PhD

Robert Orlowski, MD, PhD, University of Texas MD Anderson Cancer Center, is leading a world-class team of researchers to develop new immunotherapeutic and targeted approaches for the treatment of patients with high-risk subtypes of myeloma.
A groundbreaking immunotherapy saves young mother’s life

Emily, a 32-year-old mother of three young children, was diagnosed with non-Hodgkin lymphoma in August 2013. After a whirlwind of intense treatments over the next two years including chemotherapy, a stem cell transplant and months of hospitalization, Emily relapsed soon after each treatment. In April 2015, Emily was given a devastating prognosis – doctors said she had six months to live. But then Emily received a glimmer of hope when doctors told her of a potential new treatment. In July 2015, Emily became the third patient in the world enrolled in Kite Pharma’s clinical trial for a lifesaving treatment called CAR T-cell immunotherapy that was made possible by LLS funding. The revolutionary therapy was a success – Emily has been in remission for more than three years! Today, she enjoys spending time with her family, and has been working with LLS to raise awareness about blood cancers and raise funds for groundbreaking research so other mothers do not experience what she did.
WE ARE OUTSMARTING CANCER WITH PRECISION MEDICINE

Cancer is not a one-size-fits-all disease.

By supporting advanced genomics and molecular research, we are ushering in a new era of cancer treatment that centers on giving the right treatment to the right patient at the right time.

TIMOTHY LEY, MD
Timothy Ley, MD, Washington University School of Medicine, who led the team that sequenced the first cancer genome, is using genomic technology to identify genetic markers that can predict which patients with acute myeloid leukemia (AML) are more likely to relapse, with the goal of developing new approaches to target these mutations.

STEPHEN NIMER, MD
Stephen Nimer, MD, Sylvester Comprehensive Cancer Center, University of Miami, is driving a collaborative effort focused on advancing knowledge of the small chemical changes that regulate gene behavior. Dr. Nimer and his team are studying how to target epigenetic abnormalities to develop new therapies for AML, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

ANDREAS STRASSER, PhD, MSc, FAA
Andreas Strasser, PhD, MSc, FAA, Walter and Eliza Hall Institute of Medical Research in Australia, is leading an ambitious project centered on apoptosis, the normal process that causes impaired cells to self-destruct. The team is testing new approaches to boost apoptosis in leukemia, lymphoma and myeloma and was instrumental in developing the first approved apoptosis-targeted therapy, called venetoclax, for use in chronic lymphocytic leukemia (CLL) and, more recently, for elderly patients with acute myeloid leukemia (AML).

CONSTANTINE MITSIADES, MD, PhD
Constantine Mitsiades, MD, PhD, Dana-Farber Cancer Institute, is applying cutting-edge CRISPR/Cas9 genome editing technology to the study of myeloma. Dr. Mitsiades and his team aim to characterize which genes play an essential role in the survival and growth of myeloma cells, with the goal of uncovering new therapeutic targets to optimize treatment.
WE ARE IMPROVING CARE AND CURES FOR CHILDREN WITH BLOOD CANCERS

Dedicated pediatric cancer research is needed urgently to understand these diseases, improve care and evaluate the long-term impact of treatment.

To this end, LLS is committed to accelerating the most impactful pediatric cancer research. This is just one part of our multi-pronged approach to address the unique needs of pediatric patients, which also includes education and support services for children and their families and advocacy efforts to increase pediatric cancer research funding.

BARBARA SAVOLDO, MD, PhD
Barbara Savoldo, MD, PhD, University of North Carolina Lineberger Comprehensive Cancer Center, is developing an experimental CAR T-cell immunotherapy for acute lymphoblastic leukemia (ALL), the most common cancer in children, that would include a built-in “safety switch” to help safeguard against potential side effects of the treatment.

ADOLFO FERRANDO, MD, PhD
Adolfo Ferrando, MD, PhD, Columbia University Medical Center, is studying the genetic mutations responsible for pediatric ALL, particularly those that cause resistance to commonly used chemotherapies. For the 15-20 percent of children whose disease relapses, new treatments are desperately needed. Dr. Ferrando is advancing critical knowledge of the mechanisms of resistance, paving the way for more precisely targeted therapies.

SOHEIL MESHINCHI, MD, PhD
Soheil Meshinchi, MD, PhD, Fred Hutchinson Cancer Research Center, is working to expand knowledge of genomic characteristics that are unique to pediatric acute myeloid leukemia (AML), one of the most challenging childhood cancers to treat. His team has identified a potential biomarker for pediatric AML called mesothelin – opening the door to new targeted therapies for young patients with relapsed disease.

“I do not remember ever wanting to be anything else. My father was a doctor, and growing up, I became passionate about medicine. Leukemia research is as much of who I am as almost anything else.”

DR. ADOLFO FERRANDO, ON BECOMING A SCIENTIST
Eight-year-old Kaitlyn has had to deal with cancer for most of her young life. In fact, she was only 18 months old when she was diagnosed with acute lymphoblastic leukemia (ALL). Throughout all of her treatments, doctors’ visits and hospital stays, Kaitlyn was her brave and positive self, and continued to pursue her passion for cheerleading and dancing. “As a parent, if your child is scared, you want to be the one they reach for. You’re conditioned to think that you’re the brave one,” says her father, James. “But, when your kid touches your hand in that moment of fear and comforts you, you realize that they are the reason you’re strong.” After three years, chemotherapy stopped working for Kaitlyn. That’s when her doctor recommended a clinical trial for a revolutionary CAR T-cell immunotherapy, which LLS invested in for over two decades. In February 2015, Kaitlyn and her parents traveled nearly 1,500 miles from their home in Texas to Children’s Hospital of Philadelphia (CHOP) in Pennsylvania, where she received the lifesaving treatment. Today, the third grader is cancer free, and back to cheerleading.
WE ARE INVESTING IN PIONEERING PREVENTION RESEARCH

Today, there are no means of preventing blood cancers, but thanks to advancements in genomics and our rapidly growing understanding of the biology of cancer, LLS plans to change this.

Early detection of cancers in people before they develop blood cancer or after they have achieved remission will lead to earlier interventions.

LUCY GODLEY, MD, PhD

Lucy Godley, MD, PhD, The University of Chicago, is working to uncover the pathways that drive disease development in cancer-prone families. Once considered extremely rare, inherited forms of leukemia and lymphoma are much more common than previously thought. Discovery of these pathways will allow researchers to devise strategies to delay cancer progression or prevent it altogether.

IRENE GHOBRIAL, MD

Irene Ghobrial, MD, Dana-Farber Cancer Institute, is focused on transforming the treatment of myeloma through the early detection of precursor blood conditions. Dr. Ghobrial has received numerous LLS grants throughout her career as well as funding through TAP to support her visionary research on treatment strategies that can prevent these conditions from progressing to more serious cancers.

What makes LLS so unique is that they really think about the impact of research on patient care. We work closely with LLS to develop and expand our ideas, and LLS helps bring our work from the lab to the clinic. This makes a difference for patients every day. With support from LLS, I was able to open a clinic for patients with precursor conditions of myeloma.

DR. IRENE GHOBRIAL
Our support of innovative blood cancer research is breaking new ground in the fight against cancer. For example, we helped pioneer CAR T-cell immunotherapy, a game changing treatment approach now being tested in more than 500 clinical trials for other cancers. The Leukemia & Lymphoma Society (LLS) is at the forefront of the fight to cure cancer.
BLOOD CANCER RESEARCH LEADS THE WAY

Lifesaving breakthroughs—from precision medicine to immunotherapies—have emerged from researching cancer cells in the blood, which are easier to access and study than those in solid tumors. Many pivotal discoveries have originated from LLS-funded research, and these game changing insights and treatment approaches are now helping patients with other cancers and diseases.

1940s - 1950s
Chemotherapy, medicine used to kill cancer cells, was established first for leukemia, and later used to treat other cancers.

1970s - 1980s
The 70s brought an early understanding of genomics, which is the study of genes and their functions, laying the groundwork for precision medicine approaches to treatment.

1990s - 2000s
The 1990s saw the first FDA approval of a revolutionary targeted therapy to treat leukemia. Imatinib (Gleevec®) was the first drug to target the kinase enzyme. Today, 40+ kinase inhibitors are approved to treat other cancers.

2000s - 2020s
LLS played an instrumental role in advancing immunotherapy. In 2017, two CAR T-cell immunotherapies were FDA approved for blood cancers. This game changing approach is now being tested in more than 500 clinical trials for other cancers.

> DOWNLOAD FULL INFOGRAPHIC HERE
**Breakthroughs**

**Benjamin Ebert, MD, PhD**
Dana-Farber Cancer Institute, uncovered that mutations in blood cells of otherwise normal, healthy individuals are associated with a higher probability of developing blood cancers later in life. Dr. Ebert’s research went even deeper: his lab was the first to demonstrate that these mutations are also associated with the development of cardiovascular disease. The discovery opens up the possibility of preventative medicine to identify people at risk of developing disease years before it occurs and ultimately, devise treatment strategies to mitigate the risk.

**Selina Chen-Kiang, PhD**
Weill Cornell Medicine, discovered an innovative treatment approach that is helping both blood and breast cancer patients. While her work is focused on myeloma and lymphoma, Dr. Chen-Kiang’s discovery that a targeted therapy was effective in blocking an enzyme responsible for the division and proliferation of cancer cells, helped lead the way to that therapy, palbociclib, receiving approval from the U.S. Food and Drug Administration (FDA) in 2015 for breast cancer. With LLS support, Dr. Chen-Kiang is leading a cutting-edge research team to test palbociclib’s effectiveness in treating patients with mantle cell lymphoma (MCL).

**Ron Levy, MD**
Stanford University, pioneered a treatment approach that uses the body’s immune system to develop antibodies against invading tumor cells. His foundational work resulted in the FDA approval of the first monoclonal antibody to treat cancer, rituximab, in 1997, which is now used to treat many lymphomas and rheumatoid arthritis. Today, Dr. Levy is moving immunotherapy in a bold direction. With support from LLS’s Therapy Acceleration Program (TAP), he is testing an experimental, immune-boosting vaccine among patients with lymphoma – an approach that also shows promise for breast, colon and melanoma cancers.
REVOLUTIONARY APPROACHES FOR BLOOD CANCER ARE NOW BEING TESTED IN CLINICAL TRIALS WITH OTHER CANCERS AND DISEASES, INCLUDING:

BONE CANCER
BRAIN CANCER
BREAST CANCER
DIABETES
KIDNEY CANCER
LIVER CANCER
LUNG CANCER
LUPUS NEPHRITIS
MELANOMA
MULTIPLE SCLEROSIS
OVARIAN CANCER
PANCREATIC CANCER
PROSTATE CANCER
RHEUMATOID ARTHRITIS
STOMACH CANCER
SKIN CANCER
Valerie was in college when her father was diagnosed with an aggressive form of chronic lymphocytic leukemia (CLL) in 2005. When Valerie learned about Team In Training® (TNT), she felt inspired to take action and raise funds, and made many new friends along the way. Sadly, her father passed away in 2009. After losing her father, Valerie became even more committed to making a difference. She continued to volunteer through LLS’s Palm Beach Area Chapter and in 2010, she won Palm Beach Woman of the Year after an intense 10-week fundraising campaign. Then, five years ago, Valerie was diagnosed with multiple sclerosis. She was prescribed alemtuzumab – the same treatment that her father had taken for CLL. This targeted therapy, first approved by the FDA to treat patients with CLL in 2001, is also approved for patients with multiple sclerosis who have relapsed after previous treatment. Today, Valerie is doing well and still runs marathons. She is dedicated to helping cancer patients through her volunteer work with LLS and her career as a hematology/oncology physician assistant.
BRINGING PRECISION MEDICINE TO AML PATIENTS

Our Beat AML® Master Clinical Trial is revolutionizing acute myeloid leukemia (AML) treatment. To date, we’ve enrolled more than 400 patients.
GOING ON THE OFFENSIVE AGAINST ACUTE MYELOID LEUKEMIA

Acute myeloid leukemia (AML) is one of the most lethal blood cancers that takes more than 10,000 lives in the U.S. each year.

While therapies for other blood cancers have made remarkable leaps forward, the standard of care for AML – a combination of toxic chemotherapies – has changed very little over the past four decades. Until now.

Advancements in genomics and precision medicine are fueling a renaissance in AML research.

Today, we know that AML is not a single disease, but rather a group of more than 10 subtypes and other rare mutations. Once an elusive enemy, researchers are now able to identify and target these specific subtypes, and nine new therapies – all advanced with LLS support – have been added to our arsenal in the past two years, following approval from the U.S. Food and Drug Administration (FDA).

Still, much work remains. Only about one in four AML patients survives five years after diagnosis. LLS is leading the charge against AML through the Beat AML® Master Clinical Trial, a collaborative clinical trial that aims to change the paradigm of treatment through a precision medicine approach.

HOW IS THE BEAT AML® MASTER CLINICAL TRIAL TRANSFORMING AML TREATMENT?

The Beat AML® Master Clinical Trial is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to identify each patient’s cancer-driving genetic mutations, and then matches patients to the most promising, targeted treatment. While a typical clinical trial studies one drug or one combination of drugs, we are testing multiple therapies in multiple study arms simultaneously. This Master Trial protocol—developed with guidance from the FDA—not only has the power to bring new therapies to AML patients faster, but also has the potential to stand as a model for future clinical trials for other cancers.
LLS IS LEADING THE CHARGE AGAINST AML

LLS is bringing together the best and brightest minds across the cancer ecosystem, including three world-renowned scientists who are leading the trial: Brian Druker, MD, The Knight Cancer Institute at Oregon Health & Science University; John Byrd, MD, The Ohio State University Comprehensive Cancer Center; and Ross Levine, MD, Memorial Sloan Kettering Cancer Center. Additionally, multiple pharmaceutical companies, prominent scientists at top cancer centers, several technology companies and the FDA join us in a shared commitment to bring the promise of precision medicine to AML patients.
WHY IS THE BEAT AML® MASTER CLINICAL TRIAL SO GROUNDBREAKING?

To bring new and better treatments to AML patients in urgent need, we need to think and act boldly.

A FIRST FOR LLS:

Given our leadership in AML research – one-quarter of our annual research funding is dedicated to AML – as well as our commitment to putting patients at the forefront, LLS is uniquely qualified to drive this powerful collaboration. In fact, LLS is the first nonprofit health organization to sponsor a cancer clinical trial.

A FOCUS ON NEWLY DIAGNOSED PATIENTS:

Most AML clinical trials center on patients who have relapsed or not responded to other treatments. This trial focuses on newly diagnosed, untreated patients aged 60 or older – allowing researchers to identify genetic mutations early and offering a better chance for successful treatment.

AN UNPRECEDENTED GENOMIC SCREENING TURNAROUND:

Because AML progresses so quickly, patients need to be treated based on their particular subtype right away. For this trial, advanced genomic screening is being completed within seven days, an unparalleled timeframe.

WHAT DID THE BEAT AML® MASTER CLINICAL TRIAL ACHIEVE IN 2018?

The Beat AML® Master Clinical Trial continued to exceed expectations in 2018 as more patients and collaborators joined the fold.

More than 400 patients are enrolled in over 10 study arms at more than a dozen prestigious cancer centers across the country, including UCLA Health, Huntsman Cancer Institute at the University of Utah and Winship Cancer Institute of Emory University. More than six pharmaceutical companies are providing their innovative investigational therapies. The trial continues to gain momentum, with the goal of enrolling 1,000 patients at 15-20 cancer centers.
THANKS TO OUR BEAT AML® SUPPORTERS

$10 million+: 
Harry T. Mangurian, Jr. Foundation

$1 million - $9,999,999: 
Babich Family Foundation
Cynthia and Frank Gasztonyi Trust
Donald Porteous
Drenda Vijuk

$500,000 - $999,999: 
Pamela B. Katten Memorial Leukemia Research Foundation
Norcross Foundation
Mr. and Mrs. James F. Palmer
Clyde S. McGregor and Leane Pedersen Pope
Team b.strong

POWERING OUR ATTACK AGAINST AML

Turning loss into action, The Harry T. Mangurian Jr. Foundation continues to fuel LLS’s ambitious attack. Mr. Mangurian, a philanthropist who once owned the Boston Celtics and was a renowned horse breeder, lost his battle with AML in 2008. The Foundation, which previously donated $9 million to support LLS’s Beat AML initiatives, committed an additional $10 million in 2018 to help LLS push its pursuit of AML cures further. “We recognize that LLS is uniquely positioned among cancer organizations to actually make a difference in AML, and we are hopeful that our support of this wonderful organization will help speed new treatments and cures for the thousands of patients battling this horrible disease. In honor of our founder, Harry T. Mangurian Jr., we must find cures,” says Stephen G. Mehallis, president of the Mangurian Foundation.
We proudly recognize John Kellenyi, generous, longtime supporter and Beat AML Campaign co-chair, for his leadership, compassion and commitment.
LLS Helped Advance 19 of the 21 Blood Cancer Treatments Approved by the U.S. Food & Drug Administration (FDA) This Year.
Our sustained research investment is helping to save and improve the lives of patients. This year, the U.S. Food and Drug Administration (FDA) approved 21 treatment options for patients who urgently needed them. What’s more, LLS helped advance 19 of these advancements.

**CAR T-CELL IMMUNOTHERAPY CONTINUES TO SHOW PROMISE**

In 2017, we witnessed an historic victory for cancer patients when two revolutionary CAR (chimeric antigen receptor) T-cell immunotherapies were approved by the FDA, ushering in a new era in the treatment of cancer. This game changing approach involves genetically reprogramming a patient’s own immune cells to find and attack cancer cells. LLS supported the development of both therapies, which mark incredible progress for patients who have otherwise run out of treatment options: tisagenlecleucel (Kymriah®) for children and young adults with acute lymphoblastic leukemia (ALL) and axicabtagene ciloleucel (Yescarta®) for adults with several types of non-Hodgkin lymphoma.

In 2018, the FDA granted tisagenlecleucel (Kymriah®) its second approval, bringing a new treatment option to patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a particularly aggressive disease. In fact, only about half of the 27,000 newly diagnosed patients in the U.S. each year will achieve long-lasting disease control.

**Over the past two decades, LLS has invested more than $40 million in research at multiple institutions to advance CAR T-cell therapy for blood cancer – paving the way for research applications for solid tumors, such as cancers of the lung, breast, colon and prostate.**

LLS-funded research is making a global impact on the lives of patients: both CAR T-cell therapies are now approved for use in the European Union. We continue to invest in the most innovative science worldwide to make CAR T-cell therapies safer and more effective for more patients and easier to produce.

> **DOWNLOAD FULL INFOGRAPHIC HERE**
ADVANCEMENTS IN PRECISION MEDICINE FOR ACUTE MYELOID LEUKEMIA

Precision medicine centers on giving the right treatment to the right patient at the right time based on their genetic information and other characteristics. We are beginning to crack the code to apply precision medicine to acute myeloid leukemia (AML), one of the most daunting challenges in the blood cancers.

Each year, about 20,000 Americans are diagnosed with AML, and half of these patients are expected to have exceptionally poor outcomes. Standard treatment has typically involved intensive chemotherapy, followed by a stem cell transplant in some cases. But this approach fails most patients, the majority of whom are older adults who cannot tolerate the intensity of treatment. With more than one-quarter of our research budget invested in AML, LLS is leading the charge to address this urgent, unmet need. Our work is paying off. Researchers are now able to home in on specific genetic drivers of the disease – opening the door to a more personalized approach to treatment.

In 2018 alone, the FDA approved five new treatments for AML, and LLS helped advance all of these somewhere along their development journey:

- **ivosidenib (Tibsovo®)**, a new targeted therapy, was approved for patients with relapsed or refractory AML who have a certain genetic mutation called IDH1.

- **arsenic trioxide (Trisenox®)**, an existing drug, was approved in combination with chemotherapy for newly diagnosed adult patients with low-risk acute promyelocytic leukemia (APL).

- **glasdegib (Daurismo®)**, a new therapy, has been approved in combination with chemotherapy for the treatment of newly diagnosed adult patients with AML who are age 75 or older or who have other chronic health conditions or diseases that might preclude the use of intensive chemotherapy. The therapy targets a cell signaling pathway called Hedgehog, which is critical for the development of immature cells into cells with more specialized functions.

- **venetoclax (Venclexta®)**, an existing therapy, is now approved in combination with chemotherapy, for the treatment of newly diagnosed adult patients with AML who are age 75 or older or who have other chronic health conditions or diseases that might preclude the use of intensive chemotherapy.

- **gilteritinib (Xospata®)**, a new therapy, was approved for patients with relapsed or refractory AML, who have a genetic mutation called FLT3, which is seen in about one-third of AML patients.

Further, our groundbreaking precision medicine Beat AML® Master Clinical Trial is testing ivosidenib and gilteritinib as first-line treatments for newly diagnosed patients. We continue to fund the most promising AML research, and we provide education and support to patients and caregivers. After four decades and millions of dollars invested, we are seeing results for AML patients that give us a real reason for optimism.
Dustin was supposed to get married on December 3, 2016, but cancer turned his life upside down. Six days before his wedding, 31-year-old Dustin was diagnosed with acute promyelocytic leukemia (APL). Dustin and his fiancée, KT, stayed at the hospital for 33 days, where he underwent medical tests and began treatment. The couple canceled their wedding, and navigated finances and other aspects of their relationship while Dustin underwent eight months of chemotherapy. When Dustin and KT got married on May 7, 2017, their special day was even more meaningful. “Getting through a little bit of the worse together means appreciating the better even more,” they say. Today, Dustin is cancer free and credits research funded through LLS for saving his life. Because of advances in diagnosis and treatment, APL has been transformed from the most fatal to the most curable form of acute leukemia in adults.
IMPORTANT PROGRESS FOR ULTRA-RARE DISEASES

Ultra-rare diseases represent fewer than 1,000 cases in the U.S. per year. While the numbers are relatively small, the impact of these diseases is devastating for patients and their families. Many ultra-rare cancers are difficult to diagnose and remain incurable, and approved treatment options might not exist in some cases. Recent advancements in personalized medicine are driving more opportunities to bring much needed treatment breakthroughs to patients with ultra-rare diseases, including:

- **Tagraxofusp (Eizonris™)** a new treatment, was approved for adults and pediatric patients age two or older with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive, deadly disease that lacked a standard of care. LLS sponsored clinical trials for this novel targeted therapy through our Therapy Acceleration Program (TAP).

- **Nilotinib (Tasigna®)**, an existing therapy, was approved to treat children with a rare type of chronic myeloid leukemia (CML) in chronic phase. CML is rare in children, accounting for only about 3.1 percent of new cases of leukemia in children and young adults younger than 20 years.

- **Mogamulizumab-kpkc (Poteligeo®)**, a new therapy, was approved for two rare types of cutaneous T-cell lymphoma: mycosis fungoides (MF) and Sézary syndrome (SS), giving MF patients a new treatment option and marking the first FDA approval of a drug specifically for SS.

- **Moxetumomab pasudotox (Lumoxiti®)**, a new, first-in-class immunotoxin, was approved for patients with relapsed or refractory hairy cell leukemia (HCL), a rare, incurable, slow-growing disease. While many patients initially respond to previously approved treatment, up to 40 percent relapse, underscoring the need for more innovative therapies.
## Section 2: Our Mission

### Research

**Advancing New Lifesaving Therapies**

### 2018 FDA Approvals for Blood Cancers

LLS helped advance 19 of the 21 blood cancer treatments approved by the FDA in 2018.

<table>
<thead>
<tr>
<th>Acute Lymphoblastic Leukemia</th>
<th>Acute Myeloid Leukemia</th>
<th>Other Leukemias</th>
<th>Hodgkin Lymphoma</th>
<th>Non-Hodgkin Lymphoma</th>
<th>Myeloma</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>calaspargase pegol-mkni (Asparlas™)</td>
<td>glitriatinib (Xospata™)</td>
<td>duvelisib (Copiktra™)</td>
<td>brentuximab vedotin (Adcetris®)</td>
<td>brentuximab vedotin (Adcetris®)</td>
<td>vemurafenib (Zelboraf®)</td>
<td>carfilzomib (Kyprolis®)</td>
</tr>
<tr>
<td>bilnatumomab (Blincyto®)</td>
<td>glasdegib (Daurismo®)</td>
<td>approved for chronic lymphocytic leukemia (also approved for small cell lymphocytic lymphoma and follicular lymphoma)</td>
<td>approved for chronic lymphocytic leukemia (also approved for small cell lymphocytic lymphoma and follicular lymphoma)</td>
<td>approved for chronic lymphocytic leukemia (also approved for small cell lymphocytic lymphoma and follicular lymphoma)</td>
<td>approved for chronic lymphocytic leukemia (also approved for small cell lymphocytic lymphoma and follicular lymphoma)</td>
<td>approved for chronic lymphocytic leukemia (also approved for small cell lymphocytic lymphoma and follicular lymphoma)</td>
</tr>
<tr>
<td>ivosidenib (Tibsovo®)</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
<td>nilotinib (Tasigna®) for hairy cell leukemia</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
<td>vemurafenib (Zelboraf®)</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
</tr>
<tr>
<td>arsenic trioxide (Tiseno®)</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
<td>nilotinib (Tasigna®) for hairy cell leukemia</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
<td>vemurafenib (Zelboraf®)</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
</tr>
<tr>
<td>venetoilax (Venclexta®)</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
<td>nilotinib (Tasigna®) for hairy cell leukemia</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
<td>vemurafenib (Zelboraf®)</td>
<td>mizatamomab pasudotox (Lumoxiti)</td>
</tr>
</tbody>
</table>

* Supported by the Leukemia & Lymphoma Society
* New therapy
* CAR T-cell immunotherapy

**Note:** All other therapies were approved as new indications, reformulations of other therapies, new dosing schedules or in combination with another therapy.
When someone experiences the fear and uncertainty of a cancer diagnosis, we provide hope, guidance, education and support.

This year alone, LLS Information Specialists responded to nearly 20,000 inquiries from patients and caregivers, guiding them to our wide array of education and support services.
Dealing with a cancer diagnosis, treatment or long-term survival issues can be overwhelming. Blood cancers are complex diseases, and treatment options are evolving at a faster pace than ever.

Each day, we hear from patients and their families about the unique challenges they face, from coping with side effects to determining how to cover the cost of their care.

We at LLS believe that no one should have to face cancer alone. LLS is the leading source of free blood cancer information, education and support for patients, survivors, caregivers, families and healthcare professionals. We are committed to patients and caregivers from the time of diagnosis and throughout their cancer experience, ensuring they have access to quality, affordable and coordinated care.

WE ARE REACHING MORE PATIENTS AND CAREGIVERS WHEN THEY NEED IT MOST

For more than 20 years, LLS Information Specialists have been on the front lines of helping patients and caregivers navigate their treatments and countless emotional, financial and social challenges.

This year alone, Information Specialists responded to nearly 20,000 inquiries, connecting with patients and caregivers one-on-one and guiding them to our wide array of support services that can help.

LLS Information Specialists are master’s level oncology social workers, nurses and health educators who work with compassion to provide blood cancer patients and caregivers free personalized support, information and resources, tailored to their specific diagnosis and needs. They speak in-depth with caregivers and patients – many of them newly diagnosed – about their disease, clinical trials, financial resources, how to talk to their physicians and so much more. Information Specialists are ready to help by phone at (800) 955-4572, and live chat or email via www.LLS.org.

Meredith Barnhart
Director, Information Resource Center

Why is it so important to help patients and families soon after diagnosis?
A cancer diagnosis can bring a range of emotions and feel overwhelming. Patients and families are looking for answers, but might not know what questions to ask or where to start. By reaching patients and their loved ones soon after diagnosis, we can help them become active participants in their care, as they work with their healthcare teams to make the best decisions for them.

What was the most rewarding aspect of your work this year?
I’m inspired by the transformations I see, as patients who first connect with our Information Specialists evolve into “experts” who are truly part of the decision-making process with their healthcare teams. Through this transformation, many patients and family members go on to volunteer with LLS and provide hope to others.

What do you wish more people realized about LLS’s efforts to help patients and families?
LLS is here for you and your loved ones throughout your cancer experience. We have so many resources that can help, and we’re only a phone call away.
And you can join our efforts – nearly 8,000 volunteers across the country provide direct support to patients and families in their communities, and this support makes all the difference.
WE ARE DEDICATED TO EXPANDING CLINICAL TRIAL EDUCATION AND ENROLLMENT

Survival rates for many blood cancer patients have doubled, tripled or even quadrupled since the 1960s, thanks to breakthroughs in cancer treatment that were made possible by clinical trials.

Enrolling in a clinical trial might be the best treatment option for certain patients. That’s why LLS continues to expand our Clinical Trial Support Center (CTSC), in which specially trained nurses help patients find and enroll in clinical trials based on highly detailed, individualized assessments.

Together, our CTSC nurses and Information Specialists guide patients and caregivers through the clinical trial process, providing them with the information and support they need to overcome barriers to enrolling, including help with finances and lodging. This year, CTSC nurses provided 562 patients with in-depth clinical trial navigation and support – up an incredible 65 percent from 2017. Even more promising: three out of five patients who were assisted by the CTSC and medically eligible enrolled in an appropriate clinical trial.

By taking part in clinical trials, patients help advance our knowledge of cancer and pave the way for better care for future patients. Contact an Information Specialist at 800-955-4572 to learn more.
In 2010, Josh was with his wife on their honeymoon when he noticed a bean-sized lump on the back of his neck. After being misdiagnosed twice, Josh was diagnosed with follicular lymphoma (FL) at the age of 49. For several years, he was treated with an array of different therapy regimens. However, he continued to relapse and the FL ended up transforming into diffuse large B-cell lymphoma (DLBCL). With the help of LLS’s Clinical Trial Support Center and his oncologist, Josh enrolled in a clinical trial for CAR T-cell immunotherapy in June 2016. Today, the 57-year-old professional photographer is cancer-free and remains an avid surfer. In addition to receiving help from LLS to enroll in this clinical trial, Josh later realized that LLS played an instrumental role in advancing his therapy, investing $2.5 million in this innovative clinical trial. In fact, over the past two decades, LLS has provided $40 million in funding to develop this revolutionary approach to treating cancer and history was made in 2017 when two LLS-funded CAR T-cell immunotherapies were approved by the U.S. Food and Drug Administration.
WE ARE MAKING AN IMPACT THROUGH TRUSTED EDUCATION RESOURCES AND PROGRAMS

The healthcare landscape is constantly changing. LLS recognizes that knowledge is power, so we offer a variety of educational resources and programs to help patients, caregivers and healthcare professionals stay informed and up to date. This year, LLS:

- Distributed more than 600,000 educational booklets and fact sheets about specific diseases.
- Educated over 130,000 patients, caregivers, healthcare professionals and others – a 44 percent increase over 2017 – through live web-based and local in-person programs.
- Convened 10 regional Blood Cancer Conferences with over 3,000 patients in attendance.
- Launched a new podcast, The Bloodline with LLS, which has reached more than 7,000 listeners and covered a range of topics that matter most to patients and caregivers, from cancer-related fatigue to communicating effectively with cancer care teams.

WE ARE CONNECTING PATIENTS AND FAMILIES TO CRITICAL SUPPORT

Personal connections and one-on-one support can make all the difference in the lives of cancer patients and their families.

As a voluntary, community-based health organization, we have regional and local chapters throughout the United States and Canada to reach patients and their families in every community. We also give patients and caregivers a comfortable, welcoming place to connect online through LLS Community, where they can find support, access the latest disease and treatment information and engage with trained LLS staff. LLS offers a variety of ways for patients and caregivers to find connections and support. This year, LLS:

- Connected 1,315 volunteers with patients and caregivers diagnosed with the same disease through LLS’s Patti Robinson Kaufmann First Connection Program.
- Facilitated 113 support groups in local communities and online led by nurses and social workers.
- Reached more than 8,000 patients and caregivers through LLS Community, an online social network that provides education and support.
WE ARE BREAKING DOWN FINANCIAL BARRIERS TO CARE

We are dedicated to helping patients and families cope with the often insurmountable financial burden that cancer brings.

This year, about one-third of inquiries to LLS’s Information Specialists were from patients with financial issues and questions. In addition to our advocacy efforts to fight the rising cost of cancer care, we provide programs, resources and financial assistance to help patients in need with cancer-related expenses. This year, LLS:

• Provided $108 million in co-pay financial assistance supporting over 32,000 patients.

• Provided $529,000 through our Susan Lang Pay-It-Forward Patient Travel Assistance Program, which provided 1,176 blood cancer patients with assistance for ground transportation, air travel, and lodging related expenses.

• Committed up to $1 million in aid to support blood cancer patients impacted by natural disasters, including Hurricanes Harvey, Irma and Maria, as well as wild fires in California. As an organization that unapologetically puts patients at the forefront, LLS stepped in to help nearly 1,600 blood cancer patients and families in crisis, providing direct financial support for treatment-related travel, replacement medications and other needs.
When Barbara was diagnosed with chronic lymphocytic leukemia (CLL) at fifty years old in 1993, she faced serious financial burdens – she was unable to continue to work as a dietitian and could not afford the cost of her treatment. During that time, she reached out to LLS and received financial assistance through its Co-pay Assistance Program and Susan Lang Pay-It-Forward Patient Travel Assistance Program. After receiving immunotherapy and chemotherapy treatment, she went into remission in 2010. Today, she spends her time giving back as a longtime volunteer for LLS’s Patti Robinson Kaufmann First Connection Program, a peer-to-peer program that matches patients and their families with trained volunteers who have had similar experiences. Recently, she needed help again – and LLS was there for her. When Hurricane Irma hit her hometown of Orlando, Florida in 2017, she lost electricity in her apartment for several days, and the food in her fridge spoiled. She applied for LLS’s Hurricane Relief Program and received $500 so she could re-stock her fridge with nutritious food. Barbara says she is extremely grateful that LLS has supported her many times throughout the years, and that’s why she continues to give back to LLS today.
WE ARE HELPING CANCER PATIENTS AND CAREGIVERS TAKE CARE OF THEMSELVES

Eating well during and after cancer treatment can help patients feel better, maintain their strength, avoid treatment delays and speed recovery.

Cancer changes patients’ nutritional needs, and sorting through the vast amount of nutrition information online is a daunting task. To help cancer patients and caregivers find reliable nutrition advice and resources, LLS now offers free one-on-one nutrition consultations with a registered dietitian with expertise in oncology nutrition. This year, nearly 1,000 patients and caregivers received nutrition consultations.

Caregiving can be a demanding role, but is better managed with careful planning, good self-care and knowledge of available help. LLS is here to help. We offer a wide range of resources, information and support that help both patients and caregivers. If you are a caregiver, know that you are not alone – 29 percent of all inquiries to Information Specialists were from caregivers and more than 1,800 caregivers are on LLS Community to connect, share experiences and provide support, along with trained LLS staff. Whether you join a live, weekly online chat moderated by an oncology social worker, participate in an LLS Family Support Group in your community, or tune in to The Bloodline with LLS podcast, you can find the support that is right for you.
Through our nationwide grassroots network of more than 100,000 volunteers, we advocate for policies at the state and federal level that accelerate new treatments and ensure patients have access to care, so that they can live longer, healthier lives.

This year, our efforts have helped to increase federal cancer research funds, speed the review and approval process for new therapies, and protect patient access to lifesaving treatments.
While advances in blood cancer therapies are having a dramatic impact on the way patients are treated, critical challenges remain. At LLS, we work tirelessly to find cures, as well as to ensure patients have access to the lifesaving treatments they need. With more than 100,000 volunteer advocates across the country, we are making our voices heard on behalf of the 1.3 million blood cancer patients and survivors whom we serve. What’s more, many of the policies for which we advocate at the state and federal level are beneficial for all cancer patients.

WE ARE MAKING PROGRESS TOWARD CURES

LLS works with Congress, the U.S. Food and Drug Administration (FDA) and other federal agencies to promote new medical discoveries and speed the development of new treatments and cures. This year, key highlights of our work included:

Achieving a major win for dedicated pediatric cancer research

LLS advocates sent more than 3,100 letters to members of Congress, raising their voices to make The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act a reality—the most comprehensive childhood cancer legislation ever introduced. After Congress unanimously passed this bill, the President signed the Childhood Cancer STAR Act into law in June. LLS actively supported this legislation, which will expand opportunities for childhood cancer research and survivorship programs and make a powerful impact on the lives of childhood cancer patients, survivors and their families.

Securing new funding for cancer research

LLS advocates sent more than 2,400 letters asking Congress to increase funding for critical cancer research at the National Institutes of Health (NIH). Thanks to this and other patient advocate groups’ efforts, Congress allocated $3 billion in new research funding, which will improve cancer patients’ lives and bring us that much closer to cures.

Further, recognizing the importance of the Defense Department’s innovative cancer research program, LLS took the lead in asking Congress to make blood cancer research a priority within this program. Congress listened to our request, increasing funding for this cancer research program by $20 million—a 33 percent increase from last year—while also restoring “blood cancers” as a priority research focus in 2018.

Supporting patient-focused drug development

We continue to be a strong voice for cancer patients at the FDA, shining a light on the urgent realities they face. As cancer treatment becomes more personalized, understanding which elements of a potential treatment are most important to patients is vital. We presented the results of our National Acute Myeloid Leukemia (AML) Patient Preference Study to leadership at the FDA’s Oncology Center of Excellence (OCE) to help inform the efforts of the FDA, pharmaceutical and biotech companies, and academic researchers to understand what really matters to patients as they pursue crucial drug development for AML.
Mark was diagnosed with acute lymphoblastic leukemia when he was just two months old. As an infant, he endured intense treatment through a clinical trial and countless trips to the intensive care unit. Today, Mark is a healthy college student who is passionate about giving back and excelling at West Chester University of Pennsylvania. He openly shares his story, and visits young patients and their families in the hospital. Both Mark and his mother Jayne also volunteer with LLS through the Eastern Pennsylvania Chapter. In 2015, Mark won the coveted Student of the Year title at the chapter after raising $62,000 for LLS in seven weeks. Most recently, in April 2018, Mark and Jayne attended the Alliance for Childhood Cancer Action Days in Washington D.C. to share the patient and caregiver perspective and advocate for important pediatric cancer issues before Congress, including the Childhood Cancer STAR Act. As a member of the Alliance for Childhood Cancer, LLS worked with Congress and community partners to advance this legislation – which was signed into law in May. The law will boost pediatric cancer research efforts, unlock new insights into childhood cancer through enhanced tracking and reporting and improve the quality of life for childhood cancer survivors like Mark.
LLS ADVOCATES TOOK ACTION

While legislators debated proposals that would roll back access to meaningful health insurance coverage, LLS advocated strongly at the state and federal level for guaranteed access to stable, quality, affordable coverage. LLS advocates took action by contacting federal and state policymakers:

- More than 11,000 advocate letters sent
- More than 1,100 calls were made
- Conducted 65+ in-person meetings with policymakers

WE ARE PROTECTING PATIENTS’ ABILITY TO ACCESS THE TREATMENTS AND CARE THEY NEED

Cancer patients must have access to meaningful health insurance coverage. Their lives literally depend on it.

To this end, LLS advances solutions that uphold our core principles for meaningful coverage: guarantee access, promote affordability, ensure quality and encourage stability. This year, Congress and state policymakers debated proposals that would roll back access to meaningful health insurance coverage, including for low-income children and families enrolled in Medicaid. Throughout those debates, LLS advocated strongly at the state and federal level for guaranteed access to stable, quality, affordable coverage for the hundreds of thousands of blood cancer patients who would be impacted by these proposals.
ENSURING QUALITY INSURANCE COVERAGE

At LLS, we believe health insurance plans should meet minimum quality standards so that patients will have access to the care they need. Unfortunately, many plans fail to meet those standards.

Consider Sam’s story. A small business owner, Sam attempted to upgrade his health insurance after seeing a chiropractor for undiagnosed back pain. He wanted to be able to better cover any potential medical care he might need. A few months later, he was diagnosed with cancer and immediately began treatment. Six months into treatment, his plan refused to cover any of these medical costs, saying that his cancer was a pre-existing condition. Sam was left to battle cancer with no meaningful insurance coverage and more than $800,000 in medical debt.

As the federal government worked to finalize rules expanding the availability of the very type of plan Sam held – plans that lack many critical protections required by the Affordable Care Act – LLS pushed back through a multifaceted effort. On this issue alone, we generated 3,202 grassroots letters to Congress and the Centers for Medicare & Medicaid Services (CMS). We also urged governors, state legislators and insurance commissioners to take action to protect patients from the impact of these junk plans. By engaging our partners and working with LLS advocates to share their stories, LLS helped bring a bill to the governor’s desk in Illinois to constrain these types of plans, establishing an important model for other states.

“I was diagnosed with stage IV non-Hodgkin lymphoma and was unaware that I had purchased a limited policy. I was left with $800,000 in medical bills and no meaningful health insurance to pay for a potentially lifesaving transplant.”

SAM, CANCER SURVIVOR AND LLS ADVOCATE
PLAYING A LEADING ROLE IN ADDRESSING THE RISING COST OF CANCER CARE FOR PATIENTS

The rising cost of cancer care has reached a boiling point. In fact, about one-third of inquiries to LLS’s Information Specialists were from patients with financial issues and questions.

We believe every player in the healthcare system needs to take steps to address this dilemma by putting patients at the forefront.

In 2018, we did just that by continuing to advocate for policy reforms that could help lower overall costs and relieve patients’ financial distress. Over the past year, a number of such reforms have been implemented or are under serious consideration. For example, the FDA has sped up the review of generic drug applications, providing potentially less costly alternatives for patients. In addition, a new law passed in February will prevent Medicare Part D patients from paying more when they switch from an expensive branded biologic drug to a cheaper “biosimilar” version – a change that saves money for patients and taxpayers.

LLS worked with other advocacy organizations and stakeholders to support these and other changes, many of which were outlined in our 2017 recommendations to help reduce the cost of cancer care. While progress has been made, much work remains ahead to remove barriers to care for patients.

WORKING TO GUARANTEE ACCESS TO CARE

This year, state policymakers proposed unprecedented changes to Medicaid that would require Medicaid recipients to prove that they’re employed in order to receive coverage for their medical care.

It’s estimated that these proposals will result in thousands of low-income patients losing their only source of affordable healthcare. For that reason, LLS stood united with other patient advocates in opposition to these proposals in 13 states this year.

LLS took steps not only to defend access to Medicaid coverage, but we also joined forces with advocates in three states to expand eligibility for Medicaid. LLS believes strongly that all blood cancer patients should have access to affordable coverage for the treatment they need.
Sharon was diagnosed with myeloma in 2015. Her treatment included multiple courses of oral anti-cancer medication, countless injections, infusions, hospitalizations, a stem cell transplant and two spinal surgeries to repair cracked bones. She continues to be treated with oral anti-cancer therapy just to keep her cancer in remission. A one-month prescription with partial coverage costs her $2,000 out of pocket for the first several months of every year. At one point, Sharon had to stop taking her medications for two consecutive months because she simply did not have the money. As an LLS advocate, she has courageously shared her story with the U.S. Department of Health and Human Services and members of Congress. Sharon encourages anyone going through a cancer diagnosis to get involved with opportunities to tell their story. “Being able to share my story so that I can help and inspire others has been the most fulfilling and therapeutic treatment,” she says.
Our volunteers are part of a diverse community of supporters who represent all walks of life and bring different experiences and passions to drive forward our mission.

Beating Cancer is in Our Blood, whether you are going through a diagnosis, caring for someone who has been impacted, or simply want to know a world without blood cancer. With countless ways to engage, from raising critical funds, driving forward policies that benefit patients, and providing support to those impacted by cancer, our volunteers are truly making a difference.

Join us at www.LLS.org/Volunteer
Every day, every participant brings us closer to ending blood cancers. Together, participants across all of our campaigns helped us raise a record-breaking total of more than $250 million.

We are inspiring people across the country to run, hike, walk, sail, build teams and gain lifelong learning skills while raising funds to drive forward our mission in their own unique and powerful ways.
Through our signature fundraising campaigns, participants help us support lifesaving research, patient and healthcare provider support and education, and advocacy efforts that benefit blood cancer patients. LLS has been a pioneer in creating unique and innovative peer-to-peer fundraising campaigns, including:

**TEAM IN TRAINING**

**Fundraising Teammates celebrated at over 25 epic endurance events annually**

For over 30 years, the Team In Training campaign has supported LLS as their premier charity endurance training program—where teammates raise funds to help change the lives of those impacted by blood cancers. This campaign continues to deliver a transformative experience that inspires and supports teammates through camaraderie, coaching and an engaging journey of personal discovery. Team In Training teammates complete events in Run/Walk, Cycle, Tri, and Hike. Teammates have also started fundraising through new cycling and climbing experiences with numerous fundraisers summiting Mount Kilimanjaro, journeying to Everest Basecamp and cycling over some of Europe’s historic mountains, all while raising money and awareness for LLS. The campaign has raised more than $1.5 billion and trained more than 650,000 teammates since 1988. In FY18, the campaign significantly exceeded its revenue goals, indicating that strategic rebranding efforts are paying off and delivering results for our mission.

Visit [www.TeamInTraining.org](http://www.TeamInTraining.org) for more information.

**LIGHT THE NIGHT**

**More than 1 Million Participants Annually**

Light The Night is a powerful campaign bringing light to the darkness of cancer. One million friends, families and co-workers gather together, carrying illuminated lanterns in 140 inspirational evening walks to celebrate, honor or remember those touched by cancer.

Coming off a record-breaking year as the Peer-to-Peer Professional Forum’s Program of the Year, Light The Night continued to show growth year-over-year and moved from ninth largest peer-to-peer fundraising program in America to fifth largest, raising $700 million since 1999.

Through Light The Night, thousands of national partners, sponsors and corporate teams are helping LLS fund lifesaving research and support for patients battling cancer. The Light The Night campaign is the perfect platform for industry partners, as it allows them to bring their messages of support directly to blood cancer communities across the country. For 2018, The National Presenting Sponsors of Survivorship and Hope are Pharmacyclics and Janssen Biotech, Inc.

In 2016, Light The Night introduced Random Acts of Light. Patients and survivors across the country have been surprised with special moments, including some with favorite athletes and celebrities. This year marked the second annual Random Acts of Light Day on June 13, and garnered significant awareness on top media outlets across the country. Visit [www.LightTheNight.org](http://www.LightTheNight.org) for more information.
MAN & WOMAN OF THE YEAR

Over 10,000 Participants Annually

Man & Woman of the Year is a 10-week philanthropic competition for community leaders across the United States in honor of a local boy and girl with blood cancer.

By engaging influential community leaders, Man & Woman of the Year taps into the spirit of innovation and entrepreneurship that has allowed LLS to achieve great success in funding groundbreaking research to advance cancer cures. The winners receive LLS’s Man and Woman of the Year titles. Every dollar raised counts as one vote, and the titles are awarded to the man and woman with the most votes at the end of ten weeks. Top local fundraisers become eligible to win national titles. Visit www.MWOY.org for more information.

STUDENTS OF THE YEAR

Over 5,000 Participants Annually

The Students of the Year campaign is a seven-week competition where high school students develop and utilize professional skills such as entrepreneurship, marketing and project management to raise funds in honor of a young local cancer patient.

For the second year in a row, high school students across the country are redefining what it means to be philanthropic in today’s youth culture. Through LLS’s newest innovation in fundraising, Students of the Year, hundreds of motivated high school student teams raised significant funds for LLS’s cutting-edge cancer research and patient services. Visit www.StudentsOfTheYear.org for more information.

STUDENT SERIES

14.5 million+ Students & Their Families Participate

Student Series is a science-based philanthropy program for students from kindergarten to high school. The programs connect schools with local blood cancer patients, provide tangible life skills to participants and allow students to see the impact they’re making in the lives of others. Participating elementary and middle schools receive a proprietary STEM curriculum, aimed at sparking students’ interest in STEM through experiential, hands-on lesson plans and presentations that cover Common Core skills.

More than 14.5 million students, families and educators in 27,000 schools across the United States participate annually. The campaign has raised $368 million since 1993. Visit www.StudentSeries.org for more information.
LEUKEMIA CUP REGATTA
$66 Million+ Raised Since Inception

The Leukemia Cup Regatta is a thrilling series of events that combines the joy of on-water sports with the important task of raising money to cure cancer. At events held at yacht clubs across North America, skippers register their boats and recruit friends and colleagues to help crew and raise funds. Crew members seek donations from friends, family, co-workers and employers to sponsor their boat.

More than $66 million has been raised through the Leukemia Cup Regatta series for lifesaving research and patient services since its start more than 30 years ago. Visit [www.LeukemiaCup.org](http://www.LeukemiaCup.org) for more information.

LLS LIFESTYLE
In Its Inaugural Year 20,000 Volunteers Raised Over $3M

In October 2017, we launched LLS Lifestyle, a new way to raise funds for LLS. This new peer-to-peer fundraising platform enables LLS supporters to get creative and start their own movement. With LLS Lifestyle, every activity or passion is an opportunity to fundraise for LLS – from bake sales and birthday parties to spin class challenges and video game tournaments. The options are limitless! This year, LLS Lifestyle participants took their creativity to new heights. Among the highlights: The Bob Ross Challenge inspired anyone with a paintbrush to raise funds for LLS in honor of the beloved painter, art instructor and television host, who passed away from lymphoma. Other campaigns included multi-day mountain bike rides across South Africa, birthday fundraisers and charitable wedding registries. Visit [www.LLS.org/Lifestyle](http://www.LLS.org/Lifestyle) for more information.
PARTNERSHIPS

We are grateful to our partners and sponsors, who harness the power of their consumers, communities and employees to help fight blood cancers.

> CLICK HERE TO VIEW ALL OUR SPONSORS AND PARTNERS WHO HELP ADVANCE OUR MISSION.
FINANCIALS

We’ve always believed the most efficient way to finding cures for blood cancer is by directing as much funding as possible to the best and most innovative research, while providing patient support and education, and tirelessly advocating on behalf of patients. Your support is invested wisely.

- Total Program Services: 79.5%
- Total Supporting Services: 20.5%
- Total Expenses: 100%
Independent Auditors’ Report

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2018, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2018, and the changes in its net assets and its cash flows for the year then ended, in accordance with U.S. generally accepted accounting principles.

Report on Summarized Comparative Information
We have previously audited LLS’s 2017 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated October 27, 2017. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2017 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

KPMG LLP
November 7, 2018
## Consolidated Balance Sheet

The Leukemia & Lymphoma Society, Inc. / June 30, 2018 (with comparative amounts at June 30, 2017) (In thousands)

### Assets

<table>
<thead>
<tr>
<th>Item</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$27,628</td>
<td>41,401</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>2,767</td>
<td>3,613</td>
</tr>
<tr>
<td>Contributions and other receivables, net (note 6)</td>
<td>32,255</td>
<td>17,785</td>
</tr>
<tr>
<td>Investments (note 4)</td>
<td>319,662</td>
<td>209,421</td>
</tr>
<tr>
<td>Fixed assets, net (note 9)</td>
<td>8,614</td>
<td>10,119</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$390,926</strong></td>
<td><strong>282,339</strong></td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

<table>
<thead>
<tr>
<th>Liabilities:</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$21,907</td>
<td>21,711</td>
</tr>
<tr>
<td>Deferred revenue (note 7)</td>
<td>16,243</td>
<td>14,028</td>
</tr>
<tr>
<td>Awards and grants payable (note 2)</td>
<td>51,673</td>
<td>64,052</td>
</tr>
<tr>
<td>Co-Pay assistance payable (note 3)</td>
<td>54,696</td>
<td>20,071</td>
</tr>
<tr>
<td>Other long-term liabilities (note 10)</td>
<td>3,835</td>
<td>3,167</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>148,354</strong></td>
<td><strong>123,029</strong></td>
</tr>
</tbody>
</table>

Commitments and contingencies (notes 2, 3 and 11)

### Net assets (note 5):

<table>
<thead>
<tr>
<th>Net assets</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>149,199</td>
<td>126,993</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>90,221</td>
<td>29,161</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>3,152</td>
<td>3,156</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>242,572</strong></td>
<td><strong>159,310</strong></td>
</tr>
</tbody>
</table>

| Total liabilities and net assets                           | **$390,926** | **282,339** |

See accompanying notes to consolidated financial statements.
### Consolidated Statement of Activities

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2018  
(with summarized totals for the year ended June 30, 2017) (In thousands)

#### Operating revenue:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$251,770</td>
<td>30,338</td>
<td>—</td>
<td>282,108</td>
<td>258,525</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>$(29,198)</td>
<td></td>
<td>—</td>
<td>$(29,198)</td>
<td>$(25,955)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>222,572</td>
<td>30,338</td>
<td>—</td>
<td>252,910</td>
<td>232,570</td>
</tr>
<tr>
<td>Co-Pay contributions (note 3)</td>
<td>—</td>
<td>159,851</td>
<td>—</td>
<td>159,851</td>
<td>77,779</td>
</tr>
<tr>
<td>Therapy acceleration program contractual return (note 2)</td>
<td>3,792</td>
<td>63</td>
<td>—</td>
<td>3,855</td>
<td>29,548</td>
</tr>
<tr>
<td>Service revenue</td>
<td>9,230</td>
<td></td>
<td>—</td>
<td>9,230</td>
<td>3,847</td>
</tr>
<tr>
<td>Donated services, goods and media (note 8)</td>
<td>7,715</td>
<td>—</td>
<td>—</td>
<td>7,715</td>
<td>14,594</td>
</tr>
<tr>
<td>Legacies and other revenue</td>
<td>9,645</td>
<td>1,373</td>
<td>—</td>
<td>11,018</td>
<td>5,291</td>
</tr>
<tr>
<td>Net interest and dividend income</td>
<td>3,895</td>
<td>421</td>
<td>—</td>
<td>4,316</td>
<td>2,866</td>
</tr>
<tr>
<td>Net assets released from restrictions (note 3):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Pay assistance</td>
<td>115,797</td>
<td>(115,797)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Satisfaction of other donor restrictions</td>
<td>15,530</td>
<td>(15,530)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Total operating revenue</td>
<td>388,176</td>
<td>60,719</td>
<td>—</td>
<td>448,895</td>
<td>366,495</td>
</tr>
</tbody>
</table>

#### Operating expenses (note 8):

Program services:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>69,752</td>
<td>—</td>
<td>—</td>
<td>69,752</td>
<td>65,067</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>165,496</td>
<td>—</td>
<td>—</td>
<td>165,496</td>
<td>125,677</td>
</tr>
<tr>
<td>Public health education</td>
<td>42,940</td>
<td>—</td>
<td>—</td>
<td>42,940</td>
<td>48,138</td>
</tr>
<tr>
<td>Professional education</td>
<td>18,388</td>
<td>—</td>
<td>—</td>
<td>18,388</td>
<td>21,698</td>
</tr>
<tr>
<td>Total program services</td>
<td>296,576</td>
<td>—</td>
<td>—</td>
<td>296,576</td>
<td>260,580</td>
</tr>
</tbody>
</table>

Supporting services:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>31,831</td>
<td>—</td>
<td>—</td>
<td>31,831</td>
<td>29,049</td>
</tr>
<tr>
<td>Fundraising</td>
<td>44,468</td>
<td>—</td>
<td>—</td>
<td>44,468</td>
<td>47,656</td>
</tr>
<tr>
<td>Total supporting services</td>
<td>76,299</td>
<td>—</td>
<td>—</td>
<td>76,299</td>
<td>76,705</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>372,875</td>
<td>—</td>
<td>—</td>
<td>372,875</td>
<td>337,285</td>
</tr>
</tbody>
</table>

| Change in net assets from operating activities | 15,301 | 60,719 | — | 76,020 | 29,210 |

Foreign currency translation adjustment | 267 | (362) | (4) | (99) | (184) |

Net increase in fair value of investments (note 4) | 6,638 | 703 | — | 7,341 | 8,428 |

| Change in net assets | 22,206 | 61,060 | (4) | 83,262 | 37,454 |

#### Net Assets:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of period</td>
<td>126,993</td>
<td>29,161</td>
</tr>
<tr>
<td>End of period</td>
<td>$149,199</td>
<td>90,221</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2018 (with comparative totals for the year ended June 30, 2017) (In thousands)

<table>
<thead>
<tr>
<th>Program Services</th>
<th>Supporting Services</th>
<th>Year ended</th>
<th>Direct donor benefit costs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>June 30, 2018</td>
<td>June 30, 2017</td>
</tr>
<tr>
<td>Research</td>
<td>Patient and community service</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Awards and grants (note 2)</td>
<td></td>
<td>$44,517</td>
<td></td>
</tr>
<tr>
<td>Therapy acceleration program (note 2)</td>
<td></td>
<td>5,834</td>
<td></td>
</tr>
<tr>
<td>Clinical Trial</td>
<td></td>
<td>5,899</td>
<td></td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td></td>
<td>2,007</td>
<td></td>
</tr>
<tr>
<td>Co-Pay assistance (note 3)</td>
<td></td>
<td>108,442</td>
<td></td>
</tr>
<tr>
<td>Co-Pay processing fees</td>
<td></td>
<td>6,571</td>
<td></td>
</tr>
<tr>
<td>Donated services, goods and media (note 8)</td>
<td></td>
<td>645</td>
<td>2,636</td>
</tr>
<tr>
<td>Professional fees</td>
<td></td>
<td>3,179</td>
<td>4,429</td>
</tr>
<tr>
<td>Printing, advertising, and supplies</td>
<td></td>
<td>80</td>
<td>3,571</td>
</tr>
<tr>
<td>Occupancy, telephone and insurance (note 11)</td>
<td></td>
<td>391</td>
<td>3,279</td>
</tr>
<tr>
<td>Travel and meetings</td>
<td></td>
<td>583</td>
<td>1,757</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td></td>
<td>1,187</td>
<td>946</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td></td>
<td>24</td>
<td>1,815</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td></td>
<td>239</td>
<td>1,328</td>
</tr>
<tr>
<td>Impairment of fixed asset (note 9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td></td>
<td>514</td>
<td>1,344</td>
</tr>
<tr>
<td>Total expenses</td>
<td></td>
<td>$69,752</td>
<td>165,496</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
### Consolidated Statement of Cash Flows

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2018  
(with comparative amounts for the year ended June 30, 2017) (In thousands)

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$83,262</td>
<td>37,454</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net increase in fair value of investments</td>
<td>(7,341)</td>
<td>(8,428)</td>
</tr>
<tr>
<td>Impairment of fixed asset</td>
<td>5,434</td>
<td>5,434</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>5,499</td>
<td>7,580</td>
</tr>
<tr>
<td>Provision for uncollectible accounts</td>
<td>(630)</td>
<td>188</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>846</td>
<td>(707)</td>
</tr>
<tr>
<td>Contributions and other receivables</td>
<td>(13,840)</td>
<td>(729)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>196</td>
<td>8,056</td>
</tr>
<tr>
<td>Other long-term liability</td>
<td>668</td>
<td>1,529</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>2,215</td>
<td>1,112</td>
</tr>
<tr>
<td>Awards and grants payable</td>
<td>(12,379)</td>
<td>3,601</td>
</tr>
<tr>
<td>Co-Pay assistance payable</td>
<td>34,625</td>
<td>6,602</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>93,121</td>
<td>61,692</td>
</tr>
</tbody>
</table>

| **Cash flows from investing activities:** |          |          |
| Purchases of fixed assets             | (3,994)  | (6,187)  |
| Purchases of investments              | (150,533)| (117,279)|
| Sales of investments                  | 47,633   | 84,579   |
| **Net cash used in investing activities** | (106,894)| (38,887)|
| **Net (decrease) increase in cash and cash equivalents** | (13,773) | 22,805  |
| Cash and cash equivalents at beginning of period | 41,401   | 18,596   |
| Cash and cash equivalents at end of period | $27,628  | 41,401   |

See accompanying notes to consolidated financial statements.
1) **Organization and Summary of Significant Accounting Policies**

   \textbf{a) Organization}

   The Leukemia & Lymphoma Society, Inc. (LLS) is the world’s largest voluntary health agency dedicated to finding cures for blood cancers and providing services to blood cancer patients, their families, and caregivers. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today’s most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information regarding blood cancer and education and support programs. LLS influences public policies that accelerate the development and approval of new blood cancer therapies and advocates for all blood cancer patients and their families, helping patients navigate their cancer treatments and access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

   \textbf{b) Principles of Consolidation}

   The accompanying consolidated financial statements include the accounts of LLS that encompass the National Office of LLS and its fifty six chapters in the United States, and LLS’s not for profit affiliates, including The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), and PearlPoint Cancer Support, Inc. (PPCS). Effective March 28, 2016, LLS became the sole member of PPCS. As part of the assumption of control, LLS recognized a transfer of net assets of $552 in 2016. Effective February 8, 2018, PPCS was dissolved. All significant intercompany and intra LLS accounts and transactions have been eliminated in consolidation.

   \textbf{c) Tax-Exempt Status}

   LLS, LLSRP, LLSRF, and PPCS qualify as charitable organizations as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, are exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, as these organizations are publicly supported, contributions qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

   LLSC is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

   LLS and its related entities recognize the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to exempt purposes are subject to tax under Internal Revenue Code Section 511. There were no entities that recognized any unrelated business income tax liability for the years ended June 30, 2018 and 2017.

   \textbf{d) Estimates}

   The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, allowance for uncollectible accounts, allocation of functional expenses, and valuation of donated services, goods and media. Actual results could differ from those estimates.
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2018 (In thousands)

e) Risks and Uncertainties

LLS invests in various investment securities. Investment securities are exposed to various risks, such as interest rate risks, market risk, political risks, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS’s principal source of revenue is contributions by the general public. Accordingly, LLS’s operations are dependent upon individual contributions that are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the Co Pay program in 2018 and 2017 was funded by six and eight donors, respectively. In addition, the Beat AML Master Trial was primarily funded by seven and five donors in 2018 and 2017, respectively.

f) Summarized Financial Information

The consolidated financial statements are presented with 2017 summarized for comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2017 expenses by natural classification are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS’s 2017 consolidated financial statements from which the summarized information was derived.

g) Subsequent Events

LLS evaluated subsequent events after the balance sheet date of June 30, 2018 through November 7, 2018, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

h) Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize for its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period and/or purpose.

Permanently restricted net assets: Consist of funds that contain donor imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds is recorded as temporarily restricted net assets and is released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board approved spending policy (note 5).

i) Foreign Currency Translation

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

j) Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

Level 1: inputs are quoted or published prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2018 (Amounts in thousands)

Level 2 inputs other than quoted or published prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 unobservable inputs for the asset or liability.

LLS follows the provisions of Accounting Standards Codification (ASC) Topic 820, Fair Value Measurement, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value (NAV) per share or its equivalent, as reported by the investment managers.

The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.

k) Contributions, Grants and Deferred Revenue
Contributions are recorded as revenue, at fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

l) Service Revenue
Service revenue is accounted for as an exchange transaction whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

m) Donated Services and Goods
LLS has determined that certain of the donated services and goods it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed goods was determined based on fair market value estimates. The value of contributed services was determined for volunteers that possess specialized skills and would otherwise need to be purchased. These goods and services are recognized as revenue and expense (note 8).

n) Donated Media
LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the consolidated financial statements, was estimated based on the placement, audience, and demographics of the PSAs (note 8).

o) Cash Equivalents
Cash equivalents consist of short term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

p) Investments
Investments are stated at fair value based upon quoted or published market prices, except for the fair values of alternative investments, which are based on NAVs provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC Topic 820. These values are reviewed and evaluated by management.

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2018 (Amounts in thousands)

q) Fixed Assets and Depreciation

Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years, furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

r) Other Long-Term Liabilities

Other long term liabilities represent LLS’s liability for the Internal Revenue Code Section 457 deferred compensation plans recorded at fair market value (note 10) and straight line rent of office leases (note 11).

s) Professional Fees

Professional fees included in the consolidated financial statements principally include professional fundraising fees, contracted software development, and legal and auditing fees.

t) New Authoritative Accounting Pronouncements

The FASB issued Accounting Standards Update (ASU) 2016-14, Presentation of Financial Statements of Not for Profit Entities, which among other things, changes how not for profit entities report net asset classes, expenses and liquidity in their financial statements. The significant requirements of the new ASU include the reduction of the number of net asset classes from three to two: with donor restrictions and without donor restrictions; the presentation of expenses by their function and their natural classification in one location; quantitative and qualitative information about the management of liquid resources and availability of financial assets to meet cash needs within one year of the date of the Consolidated Balance Sheet; and retaining the option to present operating cash flows in the Consolidated Statement of Cash Flows using either the direct or indirect method. LLS plans to adopt ASU 2016-14 for the year ending June 30, 2019.

The FASB is issuing Accounting Standards Update (ASU) 2018-08, to clarify and improve the scope and the accounting guidance for contributions received and contributions made. The amendments in this Update should assist entities in (1) evaluating whether transactions should be accounted for as contributions (nonreciprocal transactions) within the scope of Topic 958, Not for Profit Entities, or as exchange (reciprocal) transactions subject to other guidance and (2) determining whether a contribution is conditional. LLS plans to adopt ASU 2018-08 for the year ending June 30, 2020. LLS is continuing to evaluate the impact of adopting this guidance on its financial statements.

2) Research

LLS has various activities that are utilized to carry out its mission as presented below:

Research

Awards and Grants: Awards and grants for research are approved by LLS’s Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multiyear grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has multiyear grant commitments of $52,216 at June 30, 2018, that are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of $51,673 and $64,052 at June 30, 2018 and 2017, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately $984 and $923 as of June 30, 2018 and 2017, respectively, have been netted against awards and grants expense.

TAP: Therapy Acceleration Program (TAP) is LLS’s strategic initiative to speed the development of blood cancer treatments and supportive diagnostics by creating business alliances with biotechnology, pharmaceutical companies, and universities. TAP provides funding for investigational new drug enabling studies and clinical stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multiyear contracts, which are

(continues »)
generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS. LLS has contract commitments of $12,745 and $9,144 at June 30, 2018 and 2017, respectively, that are conditioned upon future events and, accordingly, are not recorded. Grant refunds of approximately $591 as of June 30, 2018 have been netted against therapy acceleration program contractual return.

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows:

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>$31,328</td>
</tr>
<tr>
<td>2020</td>
<td>19,710</td>
</tr>
<tr>
<td>2021</td>
<td>11,354</td>
</tr>
<tr>
<td>Total</td>
<td>$64,961</td>
</tr>
</tbody>
</table>

TAP Contractual Return: In January 2009, as part of its TAP, LLS entered into an agreement with Celator Pharmaceuticals, Inc. (Celator) through which LLS provided funding of approximately $4,100 to Celator in support of the Phase 2 study of Celator’s lead compound Vyxeos™ (daunorubicin and cytarabine liposome for injection) for the treatment of Acute Myeloid Leukemia (AML). From 2012 through 2016, LLS provided funding of an additional $5,000 for the Phase 3 clinical study of Vyxeos™. LLS provisions of funding to Celator were based on clinical milestones.

As part of the agreement, Celator was obligated to make payments to LLS relative to the timing of the product commercialization and other liquidity events. In July 2016, Jazz Pharmaceuticals (Jazz) completed the purchase of Celator, triggering a payment of $13,716 to LLS. In late 2016, Jazz terminated the agreement with LLS triggering a one time contract termination fee of $11,612 to eliminate potential future royalty payments related to Vyxeos™. The total amount of the return to LLS from its TAP contract in Celator was $25,328. The remaining $4,220 of TAP contractual return for the year ended June 30, 2017 comes from various other TAP contracts.

For the year ended June 30, 2018, LLS received $3,855 of TAP contractual returns from various TAP contracts.

3) Co-Pay Assistance Program

Co-Pay Assistance Program: The Co Pay Assistance program offers financial assistance to patients in meeting their insurance Co Pay obligations for prescription medications or private/public health insurance premiums. Revenue is recognized when donations are received while expenses are recognized as patient applications are approved for participation according to program criteria and on availability of funding. The Co Pay Assistance payable of $54,696 and $20,071 has been established based on approved patient applications received through June 30, 2018 and 2017, respectively. At June 30, 2018, temporarily restricted net assets include $52,528 received in 2018, which are available for expenditure and are intended to be awarded in fiscal year 2019.

The following summarizes the activities of the Co-Pay Assistance program in 2018 and 2017.

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balance</td>
<td>$8,148</td>
<td>8,960</td>
</tr>
<tr>
<td>Co-Pay contributions</td>
<td>159,851</td>
<td>77,779</td>
</tr>
<tr>
<td>Investments gains</td>
<td>326</td>
<td>—</td>
</tr>
<tr>
<td>Amount expended during the year:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct assistance to patients</td>
<td>(108,442)</td>
<td>(72,969)</td>
</tr>
<tr>
<td>Other expenses incurred and reimbursed under the contract</td>
<td>(7,355)</td>
<td>(5,622)</td>
</tr>
<tr>
<td>Amounts available for expenditures in the next year</td>
<td>$52,528</td>
<td>8,148</td>
</tr>
</tbody>
</table>

(continues »)
### 4) Investments

The following tables present LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2018 and 2017:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$158,371</td>
<td>158,371</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate bonds</td>
<td>56,758</td>
<td>56,758</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Government securities and other</td>
<td>849</td>
<td>849</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>35,644</td>
<td>35,644</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>International equity</td>
<td>33,437</td>
<td>33,437</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>22,872</td>
<td>22,872</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Commodities</td>
<td>3,665</td>
<td>3,665</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$311,596</td>
<td>$311,596</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

| Investments reported at net asset value: |       |         |         |         |
| Multi strategy hedge funds | 8,066 |         |         |         |
| **Total investments reported at net asset value** | 8,066 |         |         |         |
| **$319,662** |       |         |         |         |

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$63,155</td>
<td>63,155</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate bonds</td>
<td>49,312</td>
<td>49,312</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Government securities and other</td>
<td>2,098</td>
<td>2,098</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>32,356</td>
<td>32,356</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>International equity</td>
<td>30,261</td>
<td>30,261</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>20,813</td>
<td>20,813</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Commodities</td>
<td>3,566</td>
<td>3,566</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$201,561</td>
<td>$201,561</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

| Investments reported at net asset value: |       |         |         |         |
| Multi strategy hedge funds | 7,860 |         |         |         |
| **Total investments reported at net asset value** | 7,860 |         |         |         |
| **$209,421** |       |         |         |         |

(continues »)
Investment expenses totaled $318 and $376 for the years ended June 30, 2018 and 2017, respectively. The unrealized gains were $1,802 and $4,504 for the years ended June 30, 2018 and 2017, respectively.

LLS’s alternative investments strategy is as follows:

*Multi strategy hedge funds* – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event driven strategies, distressed debt, merger and other arbitrage, and value investing.

The strategy creates indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital balance in each investment.

LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 45–95 days. By contrast, all of LLS’s nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2018 and 2017, the following table summarizes the redemption provisions for those investments reported at NAV:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quarterly</td>
<td>$6,380</td>
<td>6,265</td>
</tr>
<tr>
<td>Annual</td>
<td>1,686</td>
<td>1,595</td>
</tr>
<tr>
<td>Total</td>
<td>$8,066</td>
<td>7,860</td>
</tr>
</tbody>
</table>

As of June 30, 2018 and 2017, LLS had no unfunded commitments on its alternative investments.

5) Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2018 and 2017:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Temporarily restricted</td>
<td>Permanently restricted</td>
</tr>
<tr>
<td>Time restrictions</td>
<td>$13,702</td>
<td>—</td>
</tr>
<tr>
<td>Research</td>
<td>13,209</td>
<td>3,100</td>
</tr>
<tr>
<td>Patient service</td>
<td>10,025</td>
<td>—</td>
</tr>
<tr>
<td>Co-Pay assistance</td>
<td>52,528</td>
<td>—</td>
</tr>
<tr>
<td>Other</td>
<td>757</td>
<td>52</td>
</tr>
<tr>
<td>Total</td>
<td>$90,221</td>
<td>3,152</td>
</tr>
</tbody>
</table>

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act, which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

(continues »)
LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2018 and 2017 was 4% of ending balance at June 30, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS’s overall investment strategy.

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2018:

<table>
<thead>
<tr>
<th>Temporary restricted</th>
<th>Permanently restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$3,126</td>
<td>3,156</td>
</tr>
<tr>
<td>Investment income</td>
<td>551</td>
<td>—</td>
</tr>
<tr>
<td>Foreign currency translation adjustment</td>
<td>(3)</td>
<td>(4)</td>
</tr>
<tr>
<td>Appropriation for expenditure</td>
<td>(249)</td>
<td>—</td>
</tr>
<tr>
<td>Endowment net assets at June 30</td>
<td>$3,425</td>
<td>3,152</td>
</tr>
</tbody>
</table>

The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2017:

<table>
<thead>
<tr>
<th>Temporary restricted</th>
<th>Permanently restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$2,962</td>
<td>3,437</td>
</tr>
<tr>
<td>Investment income</td>
<td>428</td>
<td>—</td>
</tr>
<tr>
<td>Foreign currency translation adjustment</td>
<td>335</td>
<td>—</td>
</tr>
<tr>
<td>Contributions</td>
<td>—</td>
<td>5</td>
</tr>
<tr>
<td>Reclassifications</td>
<td>(347)</td>
<td>(286)</td>
</tr>
<tr>
<td>Appropriation for expenditure</td>
<td>(252)</td>
<td>—</td>
</tr>
<tr>
<td>Endowment net assets at June 30</td>
<td>$3,126</td>
<td>3,156</td>
</tr>
</tbody>
</table>

6) Contribution and Other Receivables

LLS’s contribution and other receivables at June 30, 2018 and 2017 consist of unconditional promises to give, receivables associated with service revenue, and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Contributions and other receivables consist of the following:

(continues »)
Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2018 (Amounts in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>1,539</td>
<td>2,749</td>
</tr>
<tr>
<td>Co-Pay contributions</td>
<td>15,100</td>
<td>6,000</td>
</tr>
<tr>
<td>Other restricted contribs</td>
<td>15,266</td>
<td>8,080</td>
</tr>
<tr>
<td>Service revenue and other</td>
<td>350</td>
<td>956</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 32,255</strong></td>
<td><strong>17,785</strong></td>
</tr>
</tbody>
</table>

Contributions receivables are originally recorded based on discounted cash flows using a risk-adjusted discount rate. Amounts are scheduled to be received as follows:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$ 24,400</td>
<td>13,688</td>
</tr>
<tr>
<td>1 to 5 years</td>
<td>10,076</td>
<td>5,186</td>
</tr>
<tr>
<td>After 5 years</td>
<td>—</td>
<td>25</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>34,476</strong></td>
<td><strong>18,899</strong></td>
</tr>
</tbody>
</table>

Less:

- Allowance for uncollectible accounts (987) (357)
- Discount to present value (1.5% to 5.0%) (1,234) (757)

**Total** $ 32,255 17,785

As of June 30, 2018 and 2017, 77% and 53% of gross legacies and contributions receivable were from two funding sources, respectively.

7) Deferred Revenue

The majority of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end. Deferred revenue as of June 30, 2018 and 2017 consists of the following:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grants</td>
<td>$ —</td>
<td>45</td>
</tr>
<tr>
<td>Service revenue</td>
<td>3,857</td>
<td>2,100</td>
</tr>
<tr>
<td>Special events</td>
<td>12,386</td>
<td>11,883</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 16,243</strong></td>
<td><strong>14,028</strong></td>
</tr>
</tbody>
</table>
8) **Donated Services, Goods and Media**

The value of donated goods for the Beat AML Master Trial and campaign supplies, donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donated goods</td>
<td>$1,483</td>
<td>3,552</td>
</tr>
<tr>
<td>Donated services</td>
<td>2,950</td>
<td>2,430</td>
</tr>
<tr>
<td>Donated media</td>
<td>3,282</td>
<td>8,612</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$7,715</strong></td>
<td><strong>14,594</strong></td>
</tr>
</tbody>
</table>

9) **Fixed Assets, Net**

Fixed assets at June 30, 2018 and 2017 consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold improvements</td>
<td>$2,079</td>
<td>1,795</td>
</tr>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>4,154</td>
<td>3,547</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>39,231</td>
<td>36,350</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>45,464</td>
<td>41,692</td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization</td>
<td>(36,850)</td>
<td>(31,573)</td>
</tr>
<tr>
<td><strong>Fixed assets, net</strong></td>
<td><strong>$8,614</strong></td>
<td><strong>10,119</strong></td>
</tr>
</tbody>
</table>

In 2017, an impairment of fixed assets of $5,434 was recorded for the write off of a fundraising platform that will no longer be utilized by LLS. There was no such impairment in 2018.

10) **Retirement Plans**

LLS has a defined contribution 403(b) plan covering all employees meeting age and service requirements. LLS contributions are based on a percentage of each eligible employee’s salary and years of service. Expenses under this plan aggregated $2,336 and $2,149 for the years ended June 30, 2018 and 2017, respectively.

LLS has nonqualified deferred compensation plans for its executive staff subject to the provisions of the Internal Revenue Code Section 457 (the 457 Plans). There were no expenses incurred for the years ended June 30, 2018 and 2017. The assets and liabilities of the 457 Plans are included in investments and other long term liabilities in the accompanying consolidated balance sheet and amounted to approximately $1,586 and $1,574 at June 30, 2018 and 2017, respectively.

(continues ›)
11) Lease Commitments

The leases for premises, which LLS’s National Office and chapters occupy, expire on various dates through March 31, 2031 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities.

The approximate minimum aggregate future annual rental commitments are summarized as follows:

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>$ 7,450</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>7,037</td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>6,632</td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td>5,855</td>
<td></td>
</tr>
<tr>
<td>2023</td>
<td>4,191</td>
<td></td>
</tr>
<tr>
<td>Thereafter</td>
<td>10,780</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$ 41,945</td>
<td></td>
</tr>
</tbody>
</table>

12) Joint Costs Allocation

For the years ended June 30, 2018 and 2017, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coin boards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows:

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>$ 7,463</td>
<td>12,832</td>
</tr>
<tr>
<td>Patient and community services</td>
<td>3,496</td>
<td>2,666</td>
</tr>
<tr>
<td>Public health education</td>
<td>4,884</td>
<td>5,002</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 15,843</strong></td>
<td><strong>20,500</strong></td>
</tr>
</tbody>
</table>
Research Grants

**Specialized Center of Research**

The Specialized Center of Research Program funds multidisciplinary research by teams of leading-edge academic investigators that hastens the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is comprised of at least three independent research programs that are integrated and supported by scientific core laboratories.

* William Carroll, MD, 2013
  New York University School of Medicine
  Dr. William Carroll is funded in part by ’In honor of Dione.’

* John Cleveland, PhD, 2019*
  H. Lee Moffitt Cancer Center & Research Institute

* Helen Heslop, MD, 2019*
  Baylor College of Medicine

* Craig Jordan, PhD, 2019*
  University of Colorado Denver, Anschutz Medical Campus

* Tak Mak, PhD, 2017
  University Health Network

* An Melnick, MD, 2016
  Joan & Sanford I. Weill Medical College of Cornell University
  Dr. An Melnick is funded in part by the LIUNA Charitable Foundation, the Melnyker Foundation, Angela and Gary Trouvato, The Escher Foundation, and the Jim Jacobs Charitable Foundation.

* Stephen Nimer, MD, 2018
  University of Miami
  Dr. Stephen Nimer is funded in part by the University of Miami and an anonymous donor.

* Robert Orlowski, MD, PhD, 2018
  The University of Texas MD Anderson Cancer Center

---

**Career Development Program (Scholars and Clinical Scholars)**

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

* Omar Abdel-Wahab, MD, 2017
  Sloan Kettering Institute for Cancer Research

* Philippe Armand, MD, PhD, 2019*
  Dana-Farber Cancer Institute

* Sara Armenian, DO, MPH, 2017
  Beckman Research Institute of the City of Hope

* Utiya Basu, PhD, 2016
  The Trustees of Columbia University in the City of New York, Columbia University Medical Center

* Julie Blander, PhD, 2015
  Joan & Sanford I. Weill Medical College of Cornell University

* Robert Bradley, MD, 2018
  Fred Hutchinson Cancer Research Center

* Jason Butler, PhD, 2019*
  Hackensack Meridian Health

* Dr. Jason Butler is fully funded by Celgene.

* Fernando Camargo, PhD, 2016
  Boston Children’s Hospital

* Grant Challen, PhD, 2019*
  Washington University in St. Louis

* Jianjun Chen, PhD, 2018
  University of Cincinnati

* Dr. Jianjun Chen is funded in part by The Marge and Charles Schott Foundation.

* Robert Chen, MD, 2019*
  Beckman Research Institute of the City of Hope

* Dr. Robert Chen is fully funded by Toni and Emmet Stephenson.

* Jerry Chipuk, PhD, 2017
  Icahn School of Medicine at Mount Sinai

* Dipanjak Chowdhury, PhD, 2015
  Dana-Farber Cancer Institute

* Tomek Cierpicki, PhD, 2017
  Regents of the University of Michigan

* Simona Coila, PhD, 2019*
  The University of Texas MD Anderson Cancer Center

* Alexey Danilov, MD, PhD, 2019*
  Oregon Health & Science University

* Dr. Alexey Danilov is funded in part by Dr. Evelyn Bata.

* Matthew Davids, MD, 2019*
  Dana-Farber Cancer Institute

* Dr. Matthew Davids is funded in part by Dana-Farber Cancer Institute.

* Todd Druley, MD, PhD, 2019*
  Washington University in St. Louis

* Takeshi Egawa, MD, PhD, 2018
  Washington University School of Medicine in St. Louis

* Thomas Fazzio, PhD, 2015
  University of Massachusetts Medical School

* Maria Figueroa, MD, 2019*
  University of Miami

* Benjamin Garcia, PhD, 2016
  Perelman School of Medicine at the University of Pennsylvania

* Ramiro Garzon, MD, 2016
  The Ohio State University

* Irene Ghobrial, MD, 2017
  Dana-Farber Cancer Institute

* Dr. Irene Ghobrial is funded in part by Dana-Farber Cancer Institute.

* Jolanta Grembecka, PhD, 2013
  Regents of the University of Michigan

* Dr. Jolanta Grembecka is funded in part by Team Blake.

* David Guertin, PhD, 2016
  University of Massachusetts Medical School

* Katharine Hsu, MD, PhD, 2017
  Sloan Kettering Institute for Cancer Research

* Morgan Huse, PhD, 2015
  Sloan Kettering Institute for Cancer Research

* Keesuke Ito, MD, PhD, 2019*
  Albert Einstein College of Medicine, Inc.

* Peng Ji, MD, PhD, 2018
  Northwestern University

* Hao Jiang, PhD, 2019*
  University of Virginia

* Amy Johnson, PhD, 2018**
  The Ohio State University

* Michael Kharas, PhD, 2018
  Sloan Kettering Institute for Cancer Research

* Ming Li, PhD, 2015
  Sloan Kettering Institute for Cancer Research

* Ravindra Majeti, MD, PhD, 2016
  Board of Trustees of the Leland Stanford Junior University

* Shannon McKinney-Freeman, PhD, 2019*
  St. Jude Children’s Research Hospital

---

* Newly awarded or renewed grants in Fiscal Year 2019

** Grantee prematurely terminated award in Fiscal Year 2018
SECTION 7: ACKNOWLEDGMENTS

Constantine Mitsiades, MD, PhD, 2017
Dana-Farber Cancer Institute

Ann Mulally, MD, 2018
Brigham and Women’s Hospital

Lakshmi Nayak, MD, 2019*
Dana-Farber Cancer Institute

Trista North, PhD, 2017
Boston Children’s Hospital

Ryan O’Connell, PhD, 2018
The University of Utah

Sophie Paezczesy, MD, PhD, 2015
Indiana University

Eirini Papapetrou, MD, PhD, 2019*
Icahn School of Medicine at Mount Sinai

Christopher Park, MD, PhD, 2018
New York University School of Medicine

Zhijian Qian, PhD, 2019*
University of Illinois at Chicago

Christiane Querfeld, MD, PhD, 2019*
Beckman Research Institute of the City of Hope

Michael Savona, MD, 2019*
Vanderbilt University Medical Center

Xiaobing Shi, PhD, 2017
The University of Texas MD Anderson Cancer Center

Daniel Starczynowski, PhD, 2016
Cincinnati Children’s Hospital Medical Center

Ulrich Steidl, MD, PhD, 2015
Albert Einstein College of Medicine, Inc.

Raul Tibes, MD, PhD, 2015
New York University School of Medicine

Saad Usmani, MD, 2018
Carolina’s HealthCare System

Dr. Saad Usmani is funded in part by Carolina’s HealthCare Foundation.

Geoffrey Uy, MD, 2018
Washington University in St. Louis

Christopher Vakoc, MD, PhD, 2016
Cold Spring Harbor Laboratory

Loren Walensky, MD, PhD, 2015
Dana-Farber Cancer Institute

Roland Walter, MD, PhD, 2015
Fred Hutchinson Cancer Research Center

Dr. Roland Walter is funded in memory of Dr. Oliver Press.

G. Greg Wang, PhD, 2019*
The University of North Carolina at Chapel Hill

Hans-Guido Wendel, MD, 2015
Sloan Kettering Institute for Cancer Research

Johnathan Whetstine, PhD, 2015
Massachusetts General Hospital

Catherine Wu, MD, 2015
Dana-Farber Cancer Institute

Dr. Catherine Wu is funded in part by Yetta and Harvey Saltzman.

Jianhua Yu, PhD, 2019*
Beckman Research Institute of the City of Hope

Dr. Jianhua Yu is fully funded by the Schwartz Ward Family Foundation.

Xiaochun Yu, MD, PhD, 2015
Dana-Farber Cancer Institute

Dr. Amer Zeidan is funded in part by Yetta and Harvey Saltzman.

Amer Zeidan, MBBS, 2019*
Yale University

Dr. Amer Zeidan is funded in part by Yale University.

Career Development Program (Special Fellows, Clinical Special Fellows and Fellows)

Brandon Aubrey, PhD, 2019*
Dana-Farber Cancer Institute

Will Baillie, PhD, 2019*
Yale University

Yael Ben-Nun, PhD, 2019*
Dana-Farber Cancer Institute

Shruti Bhatt, PhD, 2017
Dana-Farber Cancer Institute

George Burslem, PhD, 2018
Yale University

Sheng F. Cai, MD, PhD, 2017
Sloan Kettering Institute for Cancer Research

Hye J. Cha, PhD, 2017
Boston Children’s Hospital

Huan Chen, PhD, 2017
Boston Children’s Hospital

Pan-Yu Chen, PhD, 2019*
The Regents of the University of California, San Francisco

Ryan Corces, PhD, 2018
Board of Trustees of the Leland Stanford Junior University

Madzia Crossley, PhD, 2017
Board of Trustees of the Leland Stanford Junior University

Sarah Deng, PhD, 2017**
New York University Medical Center

Daphné Dupéré-Richer, PhD, 2019*
University of Florida

Shannon Elf, PhD, 2018
Brigham and Women’s Hospital

Jonathan Esensten, MD, PhD, 2017
The Regents of the University of California, San Francisco

Jennifer Grants, PhD, 2018
British Columbia Cancer Agency Branch

Zhaohui Gu, PhD, 2019*
St. Jude Children’s Research Hospital

Bingqian Guo, PhD, 2018
Harvard Medical School

Sarah Hainer, PhD, 2017
University of Pittsburgh

Lulu Hu, PhD, 2018
The University of Chicago

Daichi Inoue, MD, PhD, 2018
Sloan Kettering Institute for Cancer Research

Suzumune Jiang, PhD, 2019*
Board of Trustees of the Leland Stanford Junior University

Gloria Jin, PhD, 2019*
Regents of the University of Michigan

Emily Johnston, MD, 2019*
Board of Trustees of the Leland Stanford Junior University

Neeraj Joshi, PhD, 2016
The Regents of the University of California, San Francisco

Niraj Joshi, PhD, 2019*
Dana-Farber Cancer Institute

Yoon-A Kang, PhD, 2018
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Richard Jason Lamontagne, PhD, 2018
The Wistar Institute

Fides Lay, PhD, 2017
The Regents of the University of California, Los Angeles

Ruiting Lin, PhD, 2018
Emory University

Priya Mathur, PhD, 2018
The University of Chicago

Demis Menolfi, PhD, 2019*
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Linde Miles, PhD, 2019*
Sloan Kettering Institute for Cancer Research

Coraline Mylnarczyk, PhD, 2019*
Joan & Sanford I. Weill Medical College of Cornell University

Lucia Morgado Palacin, PhD, 2018
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Tomoy Muto, MD, PhD, 2019*
Cincinnati Children’s Hospital Medical Center

Shannon Oda, PhD, 2018
Fred Hutchinson Cancer Research Center

Tamara Ouspenskaia, PhD, 2018
Broad Institute, Inc.

Jelena Petrovic, PhD, 2017
The Trustees of the University of Pennsylvania, Medical Center

Bibiana Rius, PhD, 2019*
The Scripps Research Institute

Alejo Rodriguez Fraticelli, PhD, 2019*
Boston Children’s Hospital

Anne Schuetz, PhD, 2017**
University of Toronto

Noha Sharafeldin, MD, PhD, 2019*
The University of Alabama at Birmingham

Ashima Shukla, PhD, 2018
Sanford Burnham Prebys Medical Discovery Institute

Vipul Shukla, PhD, 2018
La Jolla Institute for Allergy and Immunology

Eric Smith, MD, PhD, 2018
Sloan Kettering Institute for Cancer Research

* Newly awarded or renewed grants in Fiscal Year 2019
** Grantee prematurely terminated award in Fiscal Year 2018
SECTION 7: ACKNOWLEDGMENTS

Srividya Swaminathan, PhD, 2017
Board of Trustees of the Leland Stanford Junior University

Brian Sworner, MD, PhD, 2019*
Board of Trustees of the Leland Stanford Junior University

Samuel Taylor, PhD, 2019*
Albert Einstein College of Medicine, Inc.

Elisa ten Hacken, PhD, 2018
Dana-Farber Cancer Institute

Rachel Thijssen, PhD, 2018
Walter & Eliza Hall Institute of Medical Research

Daniel Utschneider, PhD, 2019*
The University of Melbourne

Peter van Gaalen, PhD, 2017
Massachusetts General Hospital

Leandro Venturutti, PhD, 2018
Joan & Sanford I. Weill Medical College of Cornell University

Ly Vu, PhD, 2019*
Sloan Kettering Institute for Cancer Research

Adam Wilkinson, PhD, 2019*
Board of Trustees of the Leland Stanford Junior University

Matthew Witkowski, PhD, 2018
New York University School of Medicine

Dr. Matthew Witkowski is fully funded by Astellas Pharmaceutical.

Selwin Wu, PhD, 2017
Dana-Farber Cancer Institute

Min Xia, PhD, 2019*
Joan & Sanford I. Weill Medical College of Cornell University

Dongqing Yan, PhD, 2018
The University of Utah

William Yewdell, PhD, 2019*
Sloan Kettering Institute for Cancer Research

Akihide Yoshimi, MD, PhD, 2019*
Sloan Kettering Institute for Cancer Research

Noemi Zambetti, PhD, 2018
The Regents of the University of California, San Francisco

Yu Zhang, PhD, 2018
Boston Children’s Hospital

Jiajun Zhu, PhD, 2018
Sloan Kettering Institute for Cancer Research

Translational Research Program

The Translational Research Program supports outstanding investigators deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients’ lives.

Ricardo Aguiar, MD, PhD, 2017
The University of Texas Health Science Center at San Antonio

Iannis Aifantis, PhD, 2017
New York University School of Medicine

Carl Allen, MD, PhD, 2018
Baylor College of Medicine

Stephen Ansell, MD, PhD, 2018
Mayo Clinic, Rochester

Dr. Stephen Ansell is funded in part by Laurie and Guy Adami.

Fotis Asmakopoulos, MD, PhD, 2018
The Board of Regents of the University of Wisconsin System

Jon Aster, MD, PhD, 2018
Brigham and Women’s Hospital

Francesco Bertoni, MD, 2017
Fondazione per la Ricerca e la Cura dei Linfomi nel Ticino

Smita Bhatia, MD, MPH, 2019*
The University of Alabama at Birmingham

Ranjit Bindra, MD, PhD, 2018
Yale University

Bruce Blazar, MD, 2018
University of Minnesota, Twin Cities

Marie Bleakley, MD, PhD, 2017
Fred Hutchinson Cancer Research Center

Dr. Marie Bleakley is funded in part by S. Lori Brown.

Tomek Cierpicki, PhD, 2019*
Regents of the University of Michigan

George Daley, MD, PhD, 2018
Boston Children’s Hospital

Alexey Danilov, MD, PhD, 2018
Oregon Health & Science University

Hema Dave, MD, MPH, 2018
Children’s Research Institute

Dr. Hema Dave is funded in part by Paul Leinwand.

Kara Davis, DO, 2018
Board of Trustees of the Leland Stanford Junior University

Randall Davis, MD, 2017
The University of Alabama at Birmingham

Madhav Dhodapkar, MBBS, 2017
Yale University

Benjamin Ebert, MD, PhD, 2018
Dana-Farber Cancer Institute

Todd Feinberg, MD, PhD, 2017
Washington University School of Medicine in St. Louis

Andrew Feldman, MD, 2019*
Mayo Clinic, Rochester

Carolyn A. Felix, MD, 2019*
The Children’s Hospital of Philadelphia

Adolfo Ferrando, MD, PhD, 2018
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Andrés Ferreri, MD, 2017
Fondazione Centro San Raffaele

Stephen Forman, MD, 2013
Beckman Research Institute of the City of Hope

Dr. Stephen Forman is funded in part by Barbara and Gary Freedman.

Karim Gaensler, MD, 2018
The Regents of the University of California, San Francisco

Jacqueline Garcia, MD, 2018
Dana-Farber Cancer Institute

Lucy Godley, MD, PhD, 2017
The University of Chicago

Douglas Graham, MD, PhD, 2015
Emory University

Dr. Douglas Graham is funded in part by the Ella B. Cleveland Trust and the WWR Foundation.

Christian Grommes, MD, 2019*
Sloan Kettering Institute for Cancer Research

Dr. Christian Grommes is funded in memory of Christopher ‘Kit’ Carson.

Edwin Hawkins, PhD, 2018
Walter & Eliza Hall Institute of Medical Research

Timothy Hughes, MD, FRACP, FRCPA, 2017
South Australian Health & Medical Research Institute

Dr. Timothy Hughes is funded in part by Rebecca Godchaux.

Camelia Iancu-Rubin, PhD, 2019*
Icahn School of Medicine at Mount Sinai

Emmanuel Katsanis, MD, 2017
The University of Arizona

Michael Kharas, PhD, 2017
Sloan Kettering Institute for Cancer Research

Yong-Mi Kim, MD, PhD, MPH, 2017
Children’s Hospital Los Angeles

Angela Koehler, PhD, 2018
Massachusetts Institute of Technology

Larry Kwak, MD, PhD, 2018
Beckman Research Institute of the City of Hope

Dan Landau, MD, PhD, 2017
Joan & Sanford I. Weill Medical College of Cornell University

Ronald Levy, MD, 2018
Board of Trustees of the Leland Stanford Junior University

Timothy Ley, MD, 2018
Washington University School of Medicine in St. Louis

Ravindra Majeti, MD, PhD, 2019*
Board of Trustees of the Leland Stanford Junior University

Maksim Mamenkin, PhD, 2019*
Bay College of Medicine

Ani Melnick, MD, 2019*
Joan & Sanford I. Weill Medical College of Cornell University

Constantine Mitsiades, MD, PhD, 2018
Dana-Farber Cancer Institute

Charles Mullighan, MD, 2017
St. Jude Children’s Research Hospital

Stephen Nimer, MD, 2018
St. Jude Children’s Research Hospital

Joan & Sanford I. Weill Medical College of Cornell University

Ravindra Majeti, MD, PhD, 2019*
Board of Trustees of the Leland Stanford Junior University

Maksim Mamenkin, PhD, 2019*
Bay College of Medicine

* Newly awarded or renewed grants in Fiscal Year 2019
SECTION 7: ACKNOWLEDGMENTS

Jae Park, MD, 2018
Sloan Kettering Institute for Cancer Research
Dr. Jae Park is funded in part by The Hairy Cell Leukemia Foundation. Barbara and Gary Freedman, Robin and Jonathan Klein, Edith Klein, and The SASS Foundation for Medical Research.
Laura Pasqualucci, MD, 2019*
The Trustees of Columbia University in the City of New York - Morningside

Sean Post, PhD, 2019*
The University of Texas MD Anderson Cancer Center
Jun Qi, PhD, 2018
Dana-Farber Cancer Institute

Noopur Raje, MD, 2017
Massachusetts General Hospital
Katy Rezvani, MD, PhD, 2018
The University of Texas MD Anderson Cancer Center

Dr. Katy Rezvani is funded in part by the Names Family Foundation.
Steven Rosen, MD, 2019*
Beckman Research Institute of the City of Hope
Deeja Sampath, MD, PhD, 2018
The Ohio State University

Gerald Sanderson, PhD, 2017
The University of Alabama at Birmingham
Guy Sauvageau, MD, PhD, FRCPC, 2017, 2018
Institut de Recherche en Immunovirologie et en Cancérologie

Barbara Savoldo, MD, PhD, 2018
The University of North Carolina at Chapel Hill

David Scadden, MD, 2017
Massachusetts General Hospital
Mala Shanmugam, PhD, 2019*
Emory University

Lev Silberstein, MD, PhD, 2018
Fred Hutchinson Cancer Research Center

Tomasz Skorski, MD, PhD, DSc, 2019* Temple University
Daniel Starczynowski, PhD, 2017
Cincinnati Children’s Research Foundation

Ulrich Steidl, MD, PhD, 2017
Albert Einstein College of Medicine, Inc.

Enrico Tiacci, MD, 2018
University of Perugia

Dr. Enrico Tiacci is funded in part by The Hairy Cell Leukemia Foundation, Barbara and Gary Freedman, Robin and Jonathan Klein, Edith Klein, and The SASS Foundation for Medical Research.

Wei Tong, PhD, 2018
The Children’s Hospital of Philadelphia

Amit Verma, MD, 2019*
Albert Einstein College of Medicine, Inc.

Y. Lynn Wang, MD, PhD, 2017
The University of Chicago

Dr. Y. Lynn Wang is funded in part by Imagine a Cure For Leukemia Canada.

George Weiner, MD, 2017
The University of Iowa

Amitha Wickrema, MD, PhD, 2017
The University of Chicago

Kirsten Williams, MD, 2019*
Children’s Research Institute

Dr. Kirsten Williams is funded in part by The Holland C. Gregg IV Research Fund.

Kai Wucherpfennig, MD, PhD, 2019*
Dana-Farber Cancer Institute

Jianhua Yu, PhD, 2017
The Ohio State University

Andrew Zannettino, PhD, 2018
The University of Adelaide

Fenghuang Zhan, MD, PhD, 2018
The University of Iowa

Translational Research Program: Renewal

Leandro Cerchietti, MD, 2019*
Joan & Sanford I. Weill Medical College of Cornell University

John Crispino, PhD, 2014
Northwestern University

Dr. John Crispino is funded in part by the George Shields Foundation.

Maria Figueroa, MD, 2016
University of Miami

Dr. Maria Figueroa is funded in part by the LeGros Family.

Steven Grant, MD, 2018
Virginia Commonwealth University

Dr. Steven Grant is funded in part by Breeden Adams Foundation.

Mignon Loh, MD, 2019*
The Regents of the University of California, San Francisco

Feyruz Rassool, PhD, 2019*
University of Maryland at Baltimore

James Rubenstein, MD, PhD, 2016
The Regents of the University of California, San Francisco

Dr. James Rubenstein is funded in part by Lean Barchers.

Steven Treon, MD, PhD, 2018
Dana-Farber Cancer Institute

Dr. Steven Treon is funded in part by the Cora and John H. Davis Foundation and the Zegar Family Foundation.

Li Zhang, MD, PhD, 2018
University Health Network

Screen to Lead Program

The Screen to Lead Program offers drug discovery support specifically directed toward medicinal chemistry and/or drug target screening in hematological malignancies.

Adolfo Ferrando, MD, PhD, 2018
The Trustees of Columbia University in the City of New York, Columbia University Medical Center

Gary Reuther, PhD, 2018
H. Lee Moffitt Cancer Center & Research Institute

New Idea Award

A concept award that funds innovative approaches that may fundamentally change the understanding, diagnosis and/or treatment of blood cancers and related premalignant conditions.

Steven Chan, MD, PhD, 2019*
Princess Margaret Cancer Center, University Health Network

Mark Cobbold, MD, PhD, 2019*
Massachusetts General Hospital

Michael Erb, PhD, 2019*
The Scripps Research Institute

Robert Kishel, MD, PhD, 2019*
University Health Network

Andrea Reboldi, PhD, 2019*
University of Massachusetts Medical School

David Weinstock, MD, 2019*
Dana-Farber Cancer Institute

Dr. David Weinstock is funded in part by Sandra Abbott.

MPN Challenge Grants

This program is run in partnership with the MPN Research Foundation.

Angela Fleischman, MD, PhD, 2019*
The Regents of the University of California, Irvine

James Griffin, MD, 2019*
Dana-Farber Cancer Institute

Vivian Oehler, MD, 2019*
Fred Hutchinson Cancer Research Center

Stephen Oh, MD, PhD, 2019*
Washington University in St. Louis

Rebekka K. Schneider, MD, 2019*
Erasmus University Rotterdam

IWMF Grants

This program is run in partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF).

Shahrzad Jalali, PhD, 2019*
Mayo Clinic, Rochester

Zachary Hunter, PhD, 2019*
Dana-Farber Cancer Institute

Sherine Elsawa, PhD, 2019*
University of New Hampshire

* Newly awarded or renewed grants in Fiscal Year 2019
** Grantee prematurely terminated award in Fiscal Year 2018
Rising Tide Foundation for Clinical Cancer Research/LLS Patient-Focused Immunotherapy Initiative

This program is run in partnership to stimulate innovative and clinically relevant cancer research that has the highest potential for near-term patient impact in terms of clinical application, therapeutic outcomes and quality of life.

David Gottlieb, MD, 2017
The University of Sydney
Ann Leen, PhD, 2017
Baylor College of Medicine.
Ronald Levy, MD, 2017
Board of Trustees of the Leland Stanford Junior University
Dr. Ronald Levy is funded in part by Laurie and Guy Adami.
Margaret Shipp, MD, 2017
Dana-Farber Cancer Institute

Rising Tide Foundation for Clinical Cancer Research/LLS Patient-Focused Prevention Grants for Blood Cancer

This program is run in partnership to advance breakthroughs in prevention of blood cancers.

C. Ola Landgren, MD, PhD, 2019*
Sloan Kettering Institute for Cancer Research
George Vassiliou, MD, PhD 2019*
Wellcome Trust Sanger Institute

Mantle Cell Lymphoma Research Initiative

The Mantle Cell Lymphoma Research Initiative supports teams of researchers representing different disciplines and engaging in collaborative efforts to discover new approaches to treat patients with blood cancers.

Selina Chen-Kiang, PhD, 2019*
Joan & Sanford I. Weill Medical College of Cornell University
Dr. Selina Chen-Kiang is funded in part by the Sarah Cannon Fund at the HCA Foundation and Beth and Natan Vaisman.
Larry Kwak, MD, PhD 2019*
Beckman Research Institute of the City of Hope
Dr. Larry Kwak is funded in part by the Sarah Cannon Fund at the HCA Foundation and Beth and Natan Vaisman.

Special Initiatives

Peter Adamson, MD, 2019*
The Children’s Hospital of Philadelphia
Dr. Peter Adamson is funded in part by Bayer.
Carma Bylund, MD, 2019*
University of Florida
Dr. Carma Bylund is funded in part by the Carolan Research Institute.
E. Anders Kolb, MD, 2019*
Nemours/Alfred I. duPont Hospital for Children
Dr. E. Anders Kolb is funded in part by Bayer.
Mignon Loh, MD, 2019*
The Regents of the University of California, San Francisco
Dr. Ari Melnick is funded in part by the Dr. Ralph and Marian Falk Medical Research Trust.
Soheil Meshinchi, MD, PhD, 2019*
Fred Hutchinson Cancer Research Center
Dr. Soheil Meshinchi is funded in part by Bayer.

Crystal Reinhart, PhD, 2019*
University of Illinois at Champaign-Urbana
David Sabatini, MD, PhD, 2019*
Whitehead Institute for Biomedical Research
David Teachey, MD, 2019*
The Children’s Hospital of Philadelphia
Frits van Rhee, MD, PhD, 2019*
University of Arkansas for Medical Sciences
Dr. Frits van Rhee is funded in part by the Dr. Ralph and Marian Falk Medical Research Trust.

* Newly awarded or renewed grants in Fiscal Year 2019
Partnerships

Therapy Acceleration Program Partnerships

Acetylon Pharmaceuticals, Inc.
Boston, MA

Affimed Therapeutics AG
Heidelberg, Germany

Ivan Borrello, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Constellation Pharmaceuticals, Inc.
Cambridge, MA

Decoy Biosciences, Inc.
San Diego, CA

Giulio Draetta, MD, PhD
The University of Texas MD Anderson Cancer Center

Brian Druker, MD
Oregon Health & Science University

Fifty Seven, Inc.
Menlo Park, CA

Irene Ghobrial, MD
Dana-Farber Cancer Institute

Anna Jilekova, MD
Emory University

KDAC Therapeutics, Inc.
Cambridge, MA

Kiadis Pharma NV
Amsterdam, Netherlands

Kite Pharma, Inc.
Santa Monica, CA

Neximmune, Inc.
Gaithersburg, MD

Ronald Levy, MD
The Board of Trustees of the Leland Stanford Junior University

Owen O’Connor, MD, PhD
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center

OncoPep, Inc.
North Andover, MA

Selvita SA
Krakow, Poland

Stemline Therapeutics, Inc.
New York, NY

Travera, LLC
Cambridge, MA

David Wald, MD, PhD
Case Western Reserve University

Advisors

Medical & Scientific Affairs Committee

Steve Rosen, MD, FACP
Beckman Research Institute of the City of Hope Chair

Stephen Ansell, MD, PhD
Mayo Clinic, Rochester

P. Leif Bergsagel, MD
Mayo Clinic, Arizona

Ravi Bhatia, MD
The University of Alabama at Birmingham

Renzo Canetta, MD
Bristol-Myers Squibb

Alan D. D’Andrea, MD
Dana-Farber Cancer Institute

Giulio Draetta, MD, PhD
The University of Texas MD Anderson Cancer Center

Philip Frost, MD, PhD
Calesca Pharmaceuticals

Irene Ghobrial, MD
Dana-Farber Cancer Institute

Catriona Jamieson, MD, PhD
The Regents of the University of California, San Diego

Larry Kwak, MD, PhD
Beckman Research Institute of the City of Hope

Michelle LeBeau, PhD
The University of Chicago

Ross Levine, MD
Sloan Kettering Institute for Cancer Research

Jonathan D. Licht, MD
University of Florida

Alan F. List, MD
H. Lee Moffitt Cancer Center & Research Institute

Susan M. O’Brien, MD
The Regents of the University of California, Irvine

Robert Rosen
Greyhawke Capital Advisors

Franklin O. Smith, III, MD
Medpace

Therapy Acceleration Program Advisors

Dana Callow, MBA
Boston Millennia Partners Chair

C. Casey Cunningham, MD
Santé Ventures

William S. Dalton, MD, PhD
M2Gen

Giulio Draetta, MD, PhD
The University of Texas MD Anderson Cancer Center

Laura S. Kaufman, PhD, DABT
Private Consultant

Ross Levine, MD
Sloan Kettering Institute for Cancer Research

Ronald Levy, MD
The Board of Trustees of the Leland Stanford Junior University

Vern Norvies, JD
Wilson Sonsini Goodrich & Rosati

Susan M. O’Brien, MD
The Regents of the University of California, Irvine

Robert Rosen
Greyhawke Capital Advisors
2018 National Recognition & Awards Program

We are pleased to recognize the extraordinary involvement of individuals, companies, corporations and organizations for their support of LLS and its mission. Those honored give of their time, talent and treasures and have made a significant difference in the lives of so many. To find out more about our awards program, please go to http://www.LLS.org/national-awards-nomination

Congratulations to all the 2018 awardees!

2018 National Recognition & Awards Recipients

Robert de Villiers Spiral of Life Award

The Robert de Villiers Spiral of Life Award honors the founders, Rudolph and Antoinette de Villiers. In 1944, in memory of their son Robert, the de Villiers family established a foundation that today is known as The Leukemia & Lymphoma Society.

This award recognizes an individual who, through their leadership and tireless efforts to raise funds and influence policy, has advanced the overall mission of LLS.

Andy Gordon
Arizona Chapter

Charles Arnold
Illinois Chapter

Erin Zammett Ruddy
New York City Chapter

Sandy Allen-Bard
New York City Chapter

Dr. James DeGregori
Rocky Mountain Chapter

Enn Zammett Ruddy
New York City Chapter

Sandy Allen-Bard
New York City Chapter

Dr. James DeGregori
Rocky Mountain Chapter

Vision for Life Award

This award recognizes an individual, corporation or organization whose ability to think outside the box has helped to create a new fundraising campaign, program or enhanced an existing event with national potential.

Subaru of America, Inc.
National Office

Nancy Sanker
Georgia Chapter

Heartland Blood Center
Illinois Chapter

Chipotle
North Texas Chapter

Nate Demercurio
North Texas Chapter

Warrior Horses
San Diego/Hawaii Chapter

Oliver Press, MD, PhD (posthumously)
Washington/Alaska Chapter

Leroy Ball
Western Pennsylvania & West Virginia Chapter

Ted Moroz
Canada National Office

Chris Kostanecki
Greater Bay Area Chapter

Larry Gerquest
Greater Bay Area Chapter

Jason Cox
Kentucky & Southern Indiana Chapter

Avi Nessim
Long Island Chapter

Mike Davis
Long Island Chapter

Amy Stone
Minnesota Chapter

Patrick Paolini
National Capital Area Chapter

Joseph DeSapia
New York City Chapter

Don Armstrong
North Texas Chapter

Mike Mendlik
North Texas Chapter

Geri Naumcheff
Oregon SW Washington Idaho Montana Chapter

Jim Chrisman
Rocky Mountain Chapter

Donnie Hill
Tri-State Southern Ohio Chapter

Peoples
Western Pennsylvania & West Virginia Chapter

Leadership Award

This award recognizes an individual who has been active in a chapter for at least three years, and has provided expertise and guidance that have helped the chapter achieve new levels of success.

Ted Moroz
Canada National Office

Chris Kostanecki
Greater Bay Area Chapter

Larry Gerquest
Greater Bay Area Chapter

Jason Cox
Kentucky & Southern Indiana Chapter

Avi Nessim
Long Island Chapter

Mike Davis
Long Island Chapter

Amy Stone
Minnesota Chapter

Patrick Paolini
National Capital Area Chapter

Joseph DeSapia
New York City Chapter

Don Armstrong
North Texas Chapter

Mike Mendlik
North Texas Chapter

Geri Naumcheff
Oregon SW Washington Idaho Montana Chapter

Jim Chrisman
Rocky Mountain Chapter

Donnie Hill
Tri-State Southern Ohio Chapter

Peoples
Western Pennsylvania & West Virginia Chapter

Karen Hartman
Long Island Chapter

Quality of Life Award

This award recognizes a member of the medical community, a social worker, or a caregiver who has provided outstanding support, counsel or guidance to blood cancer patients or their families.

Karen Hartman
Long Island Chapter

Dr. Larry Anderson
North Texas Chapter

Daniel A. Poliyea, MD, MS
Rocky Mountain Chapter

Albert Schafer, MSW
San Diego/Hawaii Chapter

Jodi Garrett, RN BSN OCN
San Diego/Hawaii Chapter

Cheryl A Tompkins MSN, CRNP
Western Pennsylvania & West Virginia Chapter

Froedtert & the Medical College of Wisconsin
Wisconsin Chapter

Special Recognition Award

This award recognizes an individual who is deserving of recognition for their outstanding commitment to an event or program that has resulted in increasing revenue and building public awareness of LLS.

Marcia Banes
Georgia Chapter

John Bacon
Greater Bay Area Chapter

John D. Crispino, PhD
Illinois Chapter

Bobby Menges (posthumously)
Long Island Chapter

John Draper
National Capital Area Chapter

Doug Dunbar
North Texas Chapter

Jeff Gusinow
Oregon SW Washington Idaho Montana Chapter

John Reumann
Rocky Mountain Chapter

Cyndi Reinhardt
San Diego/Hawaii Chapter
Partners Against Blood Cancer Award

The Partners Against Blood Cancer Award recognizes an individual, corporation or organization that has demonstrated ongoing support and enduring commitment to LLS.

Ruby (40+ years of participation)
The Handlery Foundation
Greater Bay Area Chapter

Platinum (20+ years of participation)
Towne Properties
Tri-State Southern Ohio Chapter

Gold (15+ years of participation)
St. Joseph’s/Candler
Georgia Chapter

Silver (10+ years of participation)
Gila River Casinos
Arizona Chapter

2018 Media Awards Recipients

Recipients have a record of excellence in fundraising and promotional support, as well as educating and informing the public about LLS and its mission.

Digital
Jon Mosier
20th Century Fox, Home Entertainment
California Southland Chapter

20th Century Fox, Home Entertainment
California Southland Chapter

Rene Michel
MVP Productions
Mississippi/Louisiana Chapter

Kevin Mumphrey
MVP Productions
Mississippi/Louisiana Chapter

Anthony Keith
KKTV
Rocky Mountain Chapter

KKTU
Rocky Mountain Chapter

Radio
KSJN – Modesto
Central California Chapter

KSOF Radio
Central California Chapter

La Preciosa
KFSO Radio
Central California Chapter

Teri Ann Schliesser
iHeartMedia
Central California Chapter

Victoria Mann
Sonoma Media Group
Greater Bay Area Chapter

Sonoma Media Group
Greater Bay Area Chapter

Shelley Irwin
WGVU PBS
Michigan Chapter

WGUV PBS
Michigan Chapter

WCCO-AM Radio
Minnesota Chapter

WGFX 104.5 The Zone
Tennessee Chapter

Mike Parsons
KBEE - 898.7
Utah Chapter

KBEE - 898.7
Utah Chapter

Darrin Scott Kibbey
WVCR - 88.3 FM
Utah Chapter

Darrin Scott Kibbey
WVCR - 88.3 FM
Utah Chapter

Darrin Scott Kibbey
WVCR - 88.3 FM
Utah Chapter

Television
TBS / TNT Networks
California Southland Chapter

Alex Delgado
KSEE TV 24
Central California Chapter

KSEE TV 24
Central California Chapter

Lupita Lomeli
Univision 21
Central California Chapter

Univision 21
Central California Chapter

Good Day Sacramento
KMAX TV
Greater Sacramento Area Chapter
Dr. William Dameshek Award

This award honors the memory of Dr. William Dameshek, who was a pioneer in developing chemotherapy protocols and who founded the core hematology journal Blood and served as its editor for many, many years.

This award recognizes nationally recognized notables and celebrities who have lent their voice and image to advance the LLS mission.

Lila Javan
Founder Climb 2 Cure
California Southland Chapter

Charlie Schlatter
Acclaimed Entertainer
California Southland Chapter

John Quiñones
ABC Television Host
South Central Texas Chapter
Donors

We gratefully acknowledge the individuals, foundations and corporations that generously supported LLS’s mission during this fiscal year.

Innovation Circle
$500,000 - $999,999
Jazz Pharmaceuticals, Inc.
Lang / Stiglitz Family Fund
Gail and James Palmer
Dr. Ralph and Marian Falk Medical Research Trust
Toni and Emmet Stephenson*
Subaru of America Inc.
The Wawa Foundation

$250,000 - $499,999
AbbVie Inc.
AstraZeneca Pharmaceuticals
Barclays
Bayer
Bloomberg Philanthropies
Bristol-Myers Squibb
Carolinas HealthCare Foundation*
The Charles T. Bauer Charitable Foundation*
Charles Esten*
Fifth Third Bank
Global Franchise Group, LLC – Great American Cookies®, Hot Dog on a Stick®, Marble Slab Creamery®, MaggieMoo’s Ice Cream & Treatery®, Pretzelmaker®, and Round Table Pizza®
Kenneth and Verna Mae Jessen Trust
Kte, A Gilead Company
Merck & Company
Muy! Hamburgers LLC
The Orokawa Foundation Inc.
Pfizer, Inc.
Rising Tide
Stater Bros. Charities
Monal Carlton Stogner and Grey Stogner*
UCLA Health
Anonymous (1 donor)

$100,000-$249,000
All Round Foods Bakery Products
AbbVie Inc. courtesy of Glen Wolther and Donna Rosen
Alto-Shaam, Inc.
American Association of Physicians of Indian Origin
Anna and Dean Backer*
Bank of America
Bonnie and Sam Roditti*
Clyde Smith McGregor and LeAnn Pedersen Pope Charitable Fund
The Coleman Foundation, Inc.*
Cristine and Timothy Lindenfelser*
David Lyon
The Cypress Group
The Cyren Group
The D.J. and Terri Gerson Family Foundation*
Ellis Construction
F. M. Kirby Foundation, Inc.
The Galloway Foundation
The Hearst Foundation, Inc.
The Holland C. Gregg IV Research Fund
Incyte Corporation
Iron Bow Technologies
Jackson Family Fund
Johnson & Johnson
The John Montross Foundation
John Shumate

* Denotes multi-year commitment

President’s Circle
$10,000,000 and Above
The Harry T. Mangurian, Jr. Foundation, Inc.*

Leadership Circle
$1,000,000 - $9,999,999
Amgen Inc.
Monica and Timothy Babich*
Burlington
Celgene Corporation
Cynthia and Frank Gasztonyi*
Genentech/Biogen
Gilead Sciences Inc.
Joan and Paul Rubschlager*
LIUNA Charitable Foundation*
The Norcross Foundation, Inc.
In Memory of Herrick F. Norcross, Jr. (Rick)*
The Olive Garden Italian Restaurant
Pharmacyclics/Janssen
Donald Porteous*
Salesforce
The Sarah Cannon Fund at the HCA Foundation*
Schwartz Ward Family Foundation*
Takeda Oncology
UFCW
Walgreens
Anonymous (1 donor)

Innovation Circle
$500,000 - $999,999
Jazz Pharmaceuticals, Inc.
Lang / Stiglitz Family Fund
Gail and James Palmer
Dr. Ralph and Marian Falk Medical Research Trust
Toni and Emmet Stephenson*
Subaru of America Inc.
The Wawa Foundation

$250,000 - $499,999
AbbVie Inc.
AstraZeneca Pharmaceuticals
Barclays
Bayer
Bloomberg Philanthropies
Bristol-Myers Squibb
Carolinas HealthCare Foundation*
The Charles T. Bauer Charitable Foundation*
Charles Esten*
Fifth Third Bank
Global Franchise Group, LLC – Great American Cookies®, Hot Dog on a Stick®, Marble Slab Creamery®, MaggieMoo’s Ice Cream & Treatery®, Pretzelmaker®, and Round Table Pizza®
Kenneth and Verna Mae Jessen Trust
Kte, A Gilead Company
Merck & Company
Muy! Hamburgers LLC
The Orokawa Foundation Inc.
Pfizer, Inc.
Rising Tide
Stater Bros. Charities
Monal Carlton Stogner and Grey Stogner*
UCLA Health
Anonymous (1 donor)

$100,000-$249,000
All Round Foods Bakery Products
AbbVie Inc. courtesy of Glen Wolther and Donna Rosen
Alto-Shaam, Inc.
American Association of Physicians of Indian Origin
Anna and Dean Backer*
Bank of America
Bonnie and Sam Roditti*
Clyde Smith McGregor and LeAnn Pedersen Pope Charitable Fund
The Coleman Foundation, Inc.*
Cristine and Timothy Lindenfelser*
David Lyon
The Cypress Group
The Cyren Group
The D.J. and Terri Gerson Family Foundation*
Ellis Construction
F. M. Kirby Foundation, Inc.
The Galloway Foundation
The Hearst Foundation, Inc.
The Holland C. Gregg IV Research Fund
Incyte Corporation
Iron Bow Technologies
Jackson Family Fund
Johnson & Johnson
The John Montross Foundation
John Shumate

* Denotes multi-year commitment

President’s Circle
$10,000,000 and Above
The Harry T. Mangurian, Jr. Foundation, Inc.*

Leadership Circle
$1,000,000 - $9,999,999
Amgen Inc.
Monica and Timothy Babich*
Burlington
Celgene Corporation
Cynthia and Frank Gasztonyi*
Genentech/Biogen
Gilead Sciences Inc.
Joan and Paul Rubschlager*
LIUNA Charitable Foundation*
The Norcross Foundation, Inc.
In Memory of Herrick F. Norcross, Jr. (Rick)*
The Olive Garden Italian Restaurant
Pharmacyclics/Janssen
Donald Porteous*
Salesforce
The Sarah Cannon Fund at the HCA Foundation*
Schwartz Ward Family Foundation*
Takeda Oncology
UFCW
Walgreens
Anonymous (1 donor)
SECTION 7: ACKNOWLEDGMENTS

Silicon Valley Bank
Southern California Gas Company
Angela and Gary Trovato*
truenorth
VAE, Inc.
World Wide Technology, Inc.
Anonymous (3 donors)
Anonymous (2 donors)*

**Discovery Circle $50,000-$99,999**

ABM Industries Inc.
Acklie Charitable Foundation
Allegheny Foundation
Allstate Insurance Helping Hands Foundation
American Airlines
Moll Anderson
Arthur M. Blank Family Foundation
Biologics, Inc., a McKesson Specialty Health Company
Black Dog Charities
Blackstone Charitable Foundation
Briggs & Stratton Corporation
The C. Kenneth & Laura Baxter Foundation
Carolan Research Institute*
Caterpillar, Inc.
Cleveland Clinic
Compass Self-Storage, LLC
The Cornelius J. & Ellen P. Coakley Family Foundation
CSRA
Daiichi Sankyo C
Dana Farber Cancer Institute
DLA Piper LLP
Disney Worldwide Services, Inc.
E & J Gallo Winery
Entergy Texas
Fight Like Hell Golf JAM
Flamingo Inc.
Florida Cancer Specialists
Frances and Gertrude Levett Foundation
Garden City Turkey Trot
The GATE Foundation
GE Foundation
Generac Power Systems, Inc.
George L. Shields Foundation, Inc.
Group One Thousand One
Hannig Law
Hargrove Inc.
Dan and Heather Harrington
Hildegarde D. Becher Foundation Inc.
HM Insurance Group
Howard Family Foundation
The Huntsman Foundation
John and Kristin Hyland
The John and Frances Beck Family Foundation
J.T. Tai & Co. Foundation, Inc.
Brian Jaramillo, President, Tilden-Coil Constructors, In Memory of Ernest & Carol Jaramillo
Joerns General Contractors
Mary and Rick Kading
Kent’s Run
Koppers, Inc.
Kitchman Family Foundation Inc.
Lighthouse Investment Partners, LLC
Judy and Charlie Lynch*
Macquarie Group Foundation
Manning Family Foundation
The Marcus Foundation, Inc.
Massapequa Turkey Trot, Inc.
Mazda
McKesson Specialty Health
Miami Cancer Institute
Mindshare
 Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System
Tommy Morrison
George Moss Jr.
n2grate
North Park/Nancy A. Nasher and David Haemisegger
Pacific Union International
Pamela B. Katten Memorial Leukemia Research Foundation
Peoples Natural Gas
The Pete & Arline Harman Trust Fund
Perfumania
Pfizer Biosimilars C
The Pine Foundation
PhRMA
Piedmont Healthcare
Ping Y. Tai Foundation, Inc.
Planned Systems International
Postage Stamp Farm Foundation
PRA Health Sciences
Presidio
Brian Reinsborough*
Robert E. Gallagher Charitable Trust
SailPoint Technologies
Salt River Pima Maricopa Indian Community
Niki Salter
Sarah Cannon
George and Mary Elizabeth Smith
Southern Glazer’s Wine & Spirits
Carol and Mark Spisak
Talking Stick Resort
Teva Pharmaceuticals PA
Todd Reed McClintock Research Foundation
Toyota Motor North America
Phil Venables
Venture First
Judith Von Seldeneck
Vystar Credit Union
Washington Area Mercedes-Benz Dealers
Welsh Fargo
West Pharmaceutical Services, Inc.
Wilkinson Walsh + Eskovitz LLP
Wings of Freedom Foundation

**Advocate $25,000-$49,999**

1889 Foundation
Agios Pharmaceuticals, Inc. 🌐
AHBA, Inc.
Alverin M. Cornell Foundation
Ameren Corporation
American Chemistry Council
AmeriHealth Administrators
AmerisourceBergen Foundation
Irene Anderson
C.E. and Jean Andrews
The Annenberg Foundation
Anpac Bio
Aon Risk Solutions
Arizona Public Service (APS)
Atlantic Health System
Avella Specialty Pharmacy
Joseph Baratta
Barings
Anita and Mike Bartschat
Baylor Scott & White
Bernhard MCC
Beta Engineering
BLG Trust

BMC Atlanta
BMC Houston
Leon and Michael Borchers*
Brayton Purcell Community Foundation
Breeden-Adams Foundation
Jeff, Carol and Rebecca Burch
C.H. Robinson Worldwide
Camelback Subaru
Carefirst-Blue Cross Blue Shield
Carlos Batista Foundation
Carlson Family Foundation, Inc.
Carrrington Mortgage Services & Carrington Charitable Foundation
Carz Cruzn Inc.
Casey Construction Group
CBRE
CBRE New England
The Cellular Connection, LLC (TCC)
Centene Corporation
Chambers Family Foundation
Chickasaw Nation
Columbus Foundation
Community Foundation of Collier County
Community Foundation / Sonoma County*
Community Foundation Of New Jersey
Copper River Shared Services
Cora and John H. Davis Foundation
Costco Wholesale
Crescent Beach Challenge
CREST Insurance Group
Cruise Planners
Dallas Stars Alumni Association
Dan’s Supreme Super Markets
David C. Copley Foundation
David Polen Trust
Dealer Tire
Deloitte
Dickinson Fleet Services LLC
Michael Diers
James Dillavou
Marian Dozier
Dyer Family Foundation
Edward Jones
EFESTE Winery
The Eli and Edythe Broad Foundation
Eli Lilly
SECTION 7: ACKNOWLEDGMENTS

Enmark Stations, Inc.
Enterprise Holdings Inc.
ePLUS Technology, Inc.
EY
Fernandez Foundation
Fifth Generation, Inc.
Florentine R. Camenisch Foundation
Fox Valley Hematology & Oncology
Franklin American Mortgage Company
Freeman
Furniture Fair
Garber Automotive Group
Ethel and Bernard Garil
GEICO
GEICO Cares
General Dynamics Corporation
Giants Food
Gila River Indian Community
The Good Works Corp DBA
Greater Milwaukee Foundation, Inc.
Frank and Barbara Gumino
The Order of St. Benedict of

New Jersey

The Joseph Daly Foundation
Kaiser Permanente
Keith Zars Pools
NORTH SHORE UNIVERSITY HOSPITAL FOUNDATION

Northside Cancer Center

Ochsner Clinic Foundation
Penn Medicine, Abramson Cancer Center
Penn Station East Coast Subs
Pharmaceuticals & Janssen
Pleasant Places
Joel Plotkin
Postlethwaite & Netterville
The Pray Family Foundation
Prudential Financial
PSEG
PwC
Kathleen and Edward Quinn
Lisa and Robert Reeves
Darryl Reginelli
Marjorie Render
Richard and Terez Abatecola Foundation
Riemer & Braunstein LLP
Riley Foods
PJ and Suhail Rizvi
Doug Robinson
The Roma Charitable Foundation
Ronning Family Foundation
Robert and Nancy Rosen
RSM US Foundation
Runway to a Cure
Rush Truck Centers
James and Sally Ryan
Safford Auto & James Grimm SAIC
ST. JOSEPH'S/CANDLER
David Salmanowitz
Salmo Investments
Samuel Freeman Charitable Trust
San Jose Earthquakes
Dr. Michael and Janet Scharf
Edward Scopeitis
Sempra Energy Foundation
The Sessions Firm
Shade Tree Services Co.
Shire
Silicon Valley Community Foundation
So Long to Leukemia
Solutionreach
Theresa Smith
Tim Springer
Stand Together Music Festival
Stanford Children’s Health
Steel Dynamics, Inc.
Margaret and Donald Steiner Strike
Paul Sun
Michael Sweig
Sylvan/Laureate Foundation
T. H. Garner
Tampa Bay Lightning
Ann Taylor
TECO Energy
Tour de Court
Tolero Pharmaceuticals
Trevor Loughlin Foundation Inc.
Trial Lawyers 4 Justice
Turner Broadcasting
UC Irvine Health Care
Ultimate Software
UM Sylvester Comprehensive Cancer Center
UNC REX Healthcare
UPMC
Valero
Vanda Pharmaceuticals Inc.
Kathryn and Leo Vecellio
Venable LLP
Katy Vickery
Drenda Vijk
VWR Charitable Foundation
Zivaro
Anonymous (1 donor)

Giving Circle
$10,000-$24,999

21st Century Fox America, Inc.
4 Horsemens Charities, Inc.
60Feet6 Foundation
84 Lumber
Abacus Technical Services, LLC
Sandy Abbott
Betsy Abell
Albertsons Companies, Inc.
Alliant Insurance Services, Inc.
Allison Abel
SECTION 7: ACKNOWLEDGMENTS

Accel
Access Capital Foundation
Access Point, Inc.
Accord Healthcare, Inc.
ACE Family Foundation
Acosta Sales and Marketing Co.
Ann Milton Adams
Michael Adams
Avinash Agarwal
Air Products Foundation
Akin Gump Strauss Hauer & Feld LLC
Albert and Elaine Borchard Foundation
Albrecht Family Foundation
Alexandria Real Estate Equities Inc.
The Alice Lawrence Foundation, Inc.
Allegheny Foundation
Alliance Construction Group
AllianceData
Allmond & Company
Alston Construction
The Altschul Foundation – Reichman Memorial
Amadeus North America
American Direct Marketing Resources LLC
American Enterprise Group Inc.
American Insurance Group
American Systems
AmTrust Bank – New York Community Bank
Anadarko
Michael Anastasi
Mark and Susan Anderson
The Andrew Busch Family Foundation
Jeff and Patricia Andrews
Anonymous in honor of Diane Anthem
Joseph Antunovich
Aon
Apple Inc.
ArcherDX
Area Home Lending
Arizona Children’s Charities
Arraycon LLC
Ashton Family Fund
The Asplund Tooze Family Foundation
ASRC Federal
The Associated Credit Union Foundation LNC
Assurant
Astex Pharmaceuticals
Asuragen, Inc.
Atlantic Trust
John Audi
Austin Financial Group
Avalon Bay Communities
The Avaniessians Foundation
Eyal Avnon
Avsten Construction LLC
Craig Bacharach
Bahia Corinthian Yacht Club
Charles Baker
Harriet Baker
Baker Botts
Baker Hughes Foundation
Baker Tilly Virchow Krause, LLP
Leroy Ball
Ballinger
Blennia Balliu
Bally Capital Management, LLC
Hillary and Tom Baltimore
BankSouth Mortgage
Banner Health
Ted and Traci Barr
Bath Fitter
Douglas Baughman
Scott and Lori Baxter
Warner Baxter
Diane Baylor
BB&T
BCM One, Inc.
BD Biosciences
Beacon Capital Partners
Beat AML for Sarah Mattice
Russ Beem
BeHealth Investment Partners LLC
Beltway Cleaning Services
Ben Arnold-Sunbelt Beverage Company
Bender Foundation, Inc.
Burton Benrud
Berkshire Bank
The Bernal T. Chomeau Private Foundation
Bill Thomas Associates, Inc.
Biotechnology Innovation Organization (BIO)
Bill Bird
Bralasof
Jennifer and Brant Bishop
Stacey and Seth Blackman
Connie Blackmon
Blanchard Machinery Company, Inc.
Carole Blaska
Bloodworks Northwest
Blue Cross Blue Shield of Mississippi
BlueCross BlueShield of South Carolina
Bobby & Steve’s Auto World Youth Foundation
Nancy Boeck
Dr. David and Mrs. Natalie Bograk
Traci Bolte
Bon Secours St. Francis
Booz Allen Hamilton Inc.
Caryn Borland
Boston Properties
Boston’s Best Coffee Roasters
Bowen Engineering Corporation
John Boyle
Bradley Arant Boult Cummings Vault LLP
Melvin and Barbara Bradley
Bradshaw Automotive Group
Manisha Brahmbhatt
Brandywine Realty Trust
Barb and Tom Bresnahan
Janis E. Brewster
Jana and Warren Brickey
BriteVerify
Nancy and Mark Brodsky
Brookfield Los Angeles Builder
Michael Brooks and Marie Fotiu
Steve and Scarlet Broome
Brown Gould Kiely LLP
Morris Brown
The Bruce and Suzanne Glassman Family Charitable Foundation
The Bruce Cohen Memorial Cancer Foundation
Buch Construction
Buildings Cruise In
E. J. and Martha Burke
Harold R. Burroughs
Jennifer and Jeffrey Butler
Butler Family Foundation
John Byrd
C. Jay Moorhead Foundation
Mary Cahill
Caliber Collision
Becky and Dana Callow
Candlelighters Guild
Renzo Canetta
Cantor Fund
The Cap IV Group
Capital One Bank
TJ Caplinger
Cari M. Freeman Foundation
The Carlton Family Foundation
Carmichael Lynch
Carnival Foundation
Carolinas Healthcare System
Carrie Carroll
Linda and Don Carter
Carter Machinery Company, Inc.
Castro & Company
The Celia Lipton Farris and Victor W. Farris Foundation Inc.
Century Communities
Chad’s Light Up Leukemia
William Chandler
Chard, Snyder & Associates, Inc.
Charles Foundation
Charles Schwab
Charlotte Radiology
Chef’s Market Café & Take Away
Chemed Foundation
Ya Chen
Cherry Bekaert LLP
Chesmar Homes, LTD
Children’s Healthcare of Atlanta
Robert and Linda Chinsky
Chiramonte Construction Company
Pauline and Justin Chueh
Church & Dwight Employee Giving Fund
Cigna Health and Life Insurance Company
CINC Inc.
Circle City Foundation
Cisco Systems
Ctco
Citizens Energy Group
Ron Cizzone
Jay and Susan Clark
Clark Construction Group, LLC
Clearshark / BAiTech
Sandy Cleary
Leigh and Tommy Cleaver
Clyde Trust
CNA Foundation
CNA Insurance
Coastal Community Foundation
Cobb Strecker Dunphy & Zimmerman, Inc.
Ron Cohn
Cohn Family Foundation
CohnReznick LLP
Cole, Scott & Kissel P.A.
Commonwealth Charter Academy
Community Blood Center and Community Tissue Services
Community Care Health Plan
Community Health Network and Community Visionary Enterprises, Inc.
Concept Plus
Gail and Frank Coniglio
Robyn and Don Conlon
Connell High School
Agnes Connors
James Cook
Jean and Bernie Cooney
Debbie and Rob Copito
Coppercraft Distillery
Cord Blood Registry
Core BTS
Corelli Contractor
Corporate Office Properties Trust
Ted Couch
Courtney Knight Gaines Foundation
Covert Chevrolet Buick & GMC
Brian Cox
Madeline Craft
Crane Composites
Crane Fund for Widows and Children
Crescent Construction
Cross Country Consulting
Crow Holdings Capital Real Estate
Crown Battery
CruCon Cruise Outlet
CSI Leasing
Cub Cares Community Fund
Culver's
Blake and Kelly Cunningham
Mary Cushing Doherty
Cushman & Wakefield
CWCapital
Arlyn Cypen
D3 LLC
Jennifer and Christian Dahlberg
Dallas Stars Alumni Association
William Dalton
Thuy and Mitch Dancik
Danford Foundation
Daniel & Karen Lee Family Foundation
DataPath
David and Mikel Blair
Family Foundation
The David Adams Memorial Fund
David Spence Cancer Foundation
Kimberly Davis-Riffle
Dearborn Stamping Planting
Edward DeBartolo
Decipher Technology Studios
Eliott Davis Decosimo
Defenders
The Del Signore Family Trust
Deloitte Consulting LLP
Lee DeLorenzo
Delta Dental
Desert Institute for Spine Care
Diane's Dream Charity
Dick and Betsy DeVos Family Foundation
William Dickinson and Joe Ann Brandt
Digital Federal Credit Union
Dignity Health
Dignity Health Bakersfield
Djeruma Charitable Fund
Christopher Dillard
Sharon and Paul Dillon
Diana and Joseph Dimenna
Discovers Fund, Inc.
Dixie Construction Co., Inc.
Becky Doemland
Dominion Energy
The Donald B. and Dorothy L. Stabler Foundation
Donegal Insurance Group
Timothy Donlan
Donna and Marvin Schwartz Foundation
Donnelley Financial Foundation
The Donohue Family Foundation Inc.
Dorothy D. Smith
Charitable Foundation
Dorothy Spanos 1999 Trustee Estate
Double J Dairy
Dougherty Family Foundation
Douglas Elliman/Senadza Adzem
Doylesworth Health Cancer Institute
Michelie Drury
Duane Morris LLP
The Duke Family Foundation
Duke Cancer Institute
Doug Dunbar
Dorothea Durig
Durst Organization L.P.
The Earl and Brenda Shapiro Foundation
Easttool Secured, LLC
Deane Eastwood
Eckert Seamans Cherin & Mellott, LLC
Ed Morse Automotive Group
The Edgar and Ruth Robinson Family Foundation
The Edgerley Family Foundation
Edith M. Schweckendiek Trusts
Edward B. Dunlap Jr. Foundation
Edward Jones Arkansas Employee Supports
Jack Edwards
Ejtemai Foundation
Elekta, Inc.
Ella B. Cleveland Trust
Elm Street Development
Emerson Charitable Trust
Emser Tile
Enerplus Resources (USA) Corporation
Epzyme
The Eric Scherbarth Leukemia Research Foundation, Inc.
Erie Insurance
The Escher Foundation
The Ethel and Harry Reckson Foundation, Inc.
Etre Dermatology
Michael Euston
Excelerate Energy
Christine Faenza
Linda and Robert Faktorow
The Fama Family Charitable Fund
Fansler Foundation
Fardisheh Family Foundation
Frederick Fargo
Jennifer Farina
Jody Farrell
Edward and Ronnie Fein
Scott Ferguson
Joseph A. Ferrara and Joan Ferrara
The Ferriday Fund Charitable Trust
First Home Mortgage
First Integrity Mortgage Services
First Therapeutics USA
Florida Crystals Corporation
Florida Hospital
Florida Power & Light Company
Flushing Bank
FMC Bank
Phil and Angie Fogg
Steve and Lisa Fogg
Kyle Foley
For Finding a Cure
Force 3, Inc.
Corwin Ford
Ford Motor Company – Dearborn Truck Plant
Joseph Forgione
Alice Fortner
Jeana and Gordon Foster
Mr. and Mrs. Jon Foster
Michael Foster
Fox 5 – WTTG
Foxgordin Kitchen & Ale
Dianne and Richard Franco
Connie Frankino
Michael Frazin
Frederick Brick Works, Inc.
Randy Freitag
Friends of Katelyn – The Joyce Family
Dana Fruehling
Fullerton Financial Planning NA
Tracey Funn
Janice Gabriovske
Duane and Cheryl Gaedcke
Galen College of Nursing
Gallo Bike Club
Gallo Family Charitable Fund
Sameer Gandhi
Gardner Business Media
The Garland Company
Shannon and Raymond Garren
Craig Garrison
Brendan Garvey
Paul Gaynor
GE Credit Union
Gela, Wells & Mohr, Inc.
Genesis Gaming Solutions, Inc.
Genesys Impact, LLS
The George F. and Myra Shaskan Foundation
Dr. Gerald and Paula McNichols
Family Foundation
Get Involved Now Inc.
GetWellNetwork
Ted Gianaris
Dr. Christopher and Patricia Giannoulas
Gila River Casinos
SECTION 7: ACKNOWLEDGMENTS

Gilman Subaru Southwest
GlaxoSmithKline PA
Robert Gleason
Global Payments Inc.
Megan and Brendon Globensky
Rebecca Godchaux
Jason Goldberg
Goldberg Charitable Trust
Goldman Sachs & Co, LLC
Lee Goodwin and Linda
Schwartzstein
Govplace
Grace and Li Yu Family Foundation
Grant Thornton LLP
Laurie and Peter Grauer
Great Mills Trading Post Inc.
Greater Washington Community
Foundation
Eric and Rachel Green
Emery and Thomas Greenwood
Gregory Poole Equipment
Company, Inc.
Greystone Power Foundation Inc.
Grip It & Rip It
Larry Grisolano
Grocery Outlet Inc.
Luke Guarisco
Jason Guerin
Matthew Guerreiro and
Christina Mohr
Gulf Coast Bank & Trust Co.
H. Lee Moffitt Cancer Center &
Research Institute
HAC, Inc.
Hadden Landscape, Inc.
Richard Haideman
Lyle E. Hall
Hampton Toyota
Stephen Harder
Harkins Builders Inc.
Janet Harper
Harper Corporation General
Contractors
Albert Harris
Jennifer and Christopher Harris
Muriel Harris
Parker Harris
C Vernon Hartline
Chuck and Lisa Harthan
Thomas Hartzell
Harv’s Metro Car Wash
Raymond Haupt
Hazmat/Kenworth
HEB
Randy and Nancy Hecht
Sheila Heimze
Helen W. Bell Charitable Foundation
Kathleen and Mark Helge
Hendrick Subaru Southpoint
Wanetta Henry
JoAnn and Mark Herbert
Heritage Title
Hewlett Packard Enterprise
HID Global
Highmark & Allegheny
Health Network
Kristen and Matt Hill
Marcy and Donnie Hill
Hilcour
Erik Hinniger
Caroline and Mike Hinson
Rick Hoagland
Holland & Knight LLP
The Home Depot Foundation
Horizon Pharma USA, Inc.
Hostetler Ranches
Houston Methodist Hospital
Marcel Houtzager
Shelby Howard III
Hoxworth Blood Center
HPI
Hundred Acres Manor
Hunt Construction Group, Inc.
Niles Hushka
Hy-Vee
IBERIABANK
Icon Building Supply
ID Technologies
IDI Consulting
Immucor Gamma
Immunogen
In Loving Memory of Mark
Scheidhauer
Independent Health
Indiana Endowment LLC
Ink Technologies
Insulators International Health
Hazard Fund
International Paper
Itron
The JBG Smith Company
J.P. Morgan Charitable Giving Fund
J.R. Simplot Company Foundation
Jack Henry & Associates
Jack Link’s
Jaguar Dallas & Land Rover Dallas
James F. Deherty Charitable
Foundation
Gary Janson
The Jay and Rose Phillips Family
Foundation
JE Dunn Construction
The Jeannette and H. Peter
Kriender Charitable Trust
Jeff Paul Custom Homes
Jennifer and Robert Grunbeck
Family Foundation
Chad and Calhoun Jensen
Jim Koons Automotive
Jimboy’s Tacos
The John G. Rangos Sr. Charitable
Foundation
The John Newell Wade Foundation
John and Nancy Goldsmith Family
Foundation
John Hancock Life Insurance Co.
John Hancock Real Estate
John Moriarity & Associates
of Florida
John Wall Family Foundation
Cindy and Dan Johnson
Murray and Diana Johnson
Johnson Operating Account
Johnston Contracting
Adam Jones
Russell Jones
Jones Lang Lasalle Americas
The Joseph and Catherine Johnson
Family Foundation
Josh and Jaime Foundation
Judge Technical Services Inc.
The June and Cecil McDole
Charitable Fund
K Machine Industrial Services
Matthew Kabaker
Sandra and Stan Kahan
Susan and Dan Kane
Kasasa
Ronald Katz
Mary Beth and Christopher Kearns
Keeler Motor Car Company
Keith Busse Enterprises
Thomas Kelley*
Kenneth Bankert Foundation, Inc.
Kent Island American Legion
Post 278
Kenworth Northeast Group &
Hazmat Environmental Group, Inc.
Kerins Family
Gloria and Richard Kerns
Mary Kathleen Ketterer
Sarah Ketterer
Kettering Health Network
Keystone Capital, Inc.
Kind Therapeutics
King and Spalding
Stuart Kipnis
Chuck and Shelley Kiven
KLA Laboratories Inc.
Robin and Jonathan Klein
Carol Klinger
Penelope P. Knight
Kolache Factory
Chris Kolb
Kolter Homes/KAST Construction
Kevin Kordsmeier
Thomas Koski
Bob and Jenny Kottler
Marc Kovar
KPMG Houston
Geraldine and Charles F. Kriser
Lisa and Steven Kristel
The Kroil Family Foundation
KSM Business Services Inc.
Kenneth Kuebel and Robert Diliberto
Laborer’s Local 190
Karen and Roger LaBoube
David Labuda
Lace Up 4 Pink Inc.
Ladish Co. Foundation
LaIbe Electric Co.
Lake Family Foundation
Suzanne Badenhoop and
Guy Lamped
Brian Landrum
Harry Langenberg
Kenneth Langone
LaVerna Hahn Trust
James and Mary Lazzari
Leadiant Biosciences, Inc.
Meg and Mary Jo Leahy
Noelle Leca
Jeff Lee
Leeds Mitchell Jr., Charitable Trust
Legacy Mutual Mortgage
Legacy Star Capital Partners
Legacy Trust
John Legere
The LeGros Family
Lehigh Valley Health Network
Levine Cancer Institute
Charlene Levy
Lewis Wagner LLP
Lightning Foundation, Inc.
Linn Ligon
John and Nancy Lindahl
Peter Lindahl and Susan Biaski Lindahl
The Lindquist Family Foundation
Jessica Lindsey
Lindy Paving
Jeffrey Lipshtiz
Lisa Bilotti Foundation, Inc.
Lance Little
LLR Inc.
Paul Loeb
Lois M. Plansoen Charitable Trust
Lynda and Anthony Lomangino
Lori Loo
Nick Loporcaro
The Lotz Family Foundation
Louisville Metro Government
William Loveless
Kent Lynch
M2Gen
Mabee / Gumpert Philanthropic Fund
MacArthur Foundation
Madison Capital Group LLC
Mack Madness, Inc.
Sean and Vanessa Magee
Bob Maher
Major Hyundai
Deborah Maine
Chuck Malk
Nancy and David Malone
Manatt, Phelps and Phillips, LLP
Manchester Life Foundation
Craig Manske
Barbara and Joel Marcus
Randal Margo
Marie-Josee and Henry R. Kravis Foundation
John Marten
John Martin
Lucy Martin & Family In Memory of Ron Martin
Mary P. Sterling Foundation
Masco Cabinetry
Michael Maser
Dr. Jeff and Marie Matous
Kim and Matthew Mausser
Maverick Capital Foundation
Jeffrey and Katrina Mayer
MB Financial Bank
Dustin McCullough
Charles McCall
Sandra and Thomas McCarthy
Mike and Candace McCaw
Henry McCreary, Jr.
Matthew and Julie McDonough
Erin and Sean McGould
Michele and Scott McMullin
William McNitt
MD Anderson Cancer Center
MEC Leukemia Survivorship Foundation
Medical City Dallas Hospital
Medical City Fort Worth
Medical Mutual
Medidata
MedStar Georgetown
Medstar Shah MSO LLC
Meining Family Foundation
Samantha Meinsen
Joseph Meisner
The Memorial Foundation
Craig Meneer
Mercy Health Partners - SWO
Meritor, Inc.
Kathleen Meriwether
Merrill Lynch
Susanna Merriman
Metromont Corporation
MGH Advertising, Inc.
MGH Cancer Center
Miami Parking Authority
Michael & Nicole Gerdin Family
Bob and Brenda Michaels
Michigan Pathology Specialists
Microsoft
Middle Street Partners, LLC
Mike Swalley Endowment
Milbank, Tweed, Hadley & McCloy LLP
Miles & Stockbridge LLP
Chris Miller
Natalie and JT Miller
Mineola Properties LLC
Minnesota Twins Community Fund
Minto Communities
Alan Miyasaka
Mizuho Americas
MN Chapter Board of Trustees
Moffatt & Nichol
Max Mohammadi
Monday Properties
Raymond Montminy
Monumental Sports & Entertainment Foundation
Colin Moore
Wendy and Charles Moore
Morgan H. Johnson Family
Morgan Stanley Foundation
Jonathan Morris
Joseph Morrison
Susan and Marvin Moser
Ali and Judge Moss
Aaron Motwani
Mountain America Federal Credit Union
Movement Foundation, Inc.
The MPB Charitable Foundation
MRA
MUFG
Murray Law Firm
Muskgog Health Care Center
Myron H. Ackerman Trust
Stacey and Rick Nadeau
The Najim Family Foundation
Larry Nance
NASA Federal Credit Union
NASCAR Foundation
The Naserian Foundation Inc.
Nashville Wine Auction
National Rural Utilities Cooperative Finance Corporation
Navarro Family Foundation
NCF Interiors
Nebraska Medicine
Nehring Construction, Inc.
Pabco Construction Corp.
Parks Cancer Institute
Parks Ortho Hospital
Parkview Physicians Group
Patch Painters and Allied Trades for Children’s PathGroup
Edward Patterson and Krista Coppola Patterson
Jerry Paul
Paul & Joan Rubschiager Foundation
Paul and Beryl Greetin Foundation
The Paul E. Singer Foundation
Paul & Joan Rubschiager Foundation
NASCAR Foundation
The Paul E. Singer Foundation
Peck Madigan, Jones, Inc.
Pegasus Builders
Penn Color
Peoples Health Network
Peoples Health Network
People’s United Bank
Nacho Perez
Northwest Mutual
Northwestern Mutual Foundation
Northwestern Mutual Financial Network
North Western Health
NorthwestHealth
Norton Healthcare
Norton Rose Fulbright US LLP
Nova Construction Services LLC
Novant Health
NVIDIA
Jerome Oakley
O&H, Inc.
OCDM, Inc.
Ocdm, Inc.
Odin, Feldman & Pittleman P.C.
OHC
OK Reality
O’Malley & Myers LLP
The Omer Foundation
Brian O’Neill
Orange Theory Fitness
Oregon Oncology Specialists
Ostroff Associates
Lori and John Overbeck
Pabco Construction Corp.
Pacific Service Credit Union
Dan Paolini
Papa John’s of Iowa
Paquette & Co.
PAP Electrical Contractors, Inc.
Eric Parks
Parkview Cancer Institute
Parkview Ortho Hospital
Parkview Physicians Group
Patch Painters and Allied Trades for Children’s PathGroup
Edward Patterson and Krista Coppola Patterson
Jerry Paul
Paul & Joan Rubschiager Foundation
Paul and Beryl Greetin Foundation
The Paul E. Singer Foundation
Peck Madigan, Jones, Inc.
Pegasus Builders
Penn Color
Peoples Health Network
Peoples Health Network
People’s United Bank
Nacho Perez
Northwest Mutual
Northwestern Mutual Foundation
Northwestern Mutual Financial Network
North Western Health
NorthwestHealth
Norton Healthcare
Norton Rose Fulbright US LLP
Nova Construction Services LLC
Novant Health
NVIDIA
Jerome Oakley
O&H, Inc.
OCDM, Inc.
Ocdm, Inc.
Odin, Feldman & Pittleman P.C.
OHC
OK Reality
O’Malley & Myers LLP
The Omer Foundation
Brian O’Neill
Orange Theory Fitness
Oregon Oncology Specialists
Ostroff Associates
Lori and John Overbeck
Pabco Construction Corp.
Pacific Service Credit Union
Dan Paolini
Papa John’s of Iowa
Paquette & Co.
PAP Electrical Contractors, Inc.
Eric Parks
Parkview Cancer Institute
Parkview Ortho Hospital
Parkview Physicians Group
Patch Painters and Allied Trades for Children’s PathGroup
Edward Patterson and Krista Coppola Patterson
Jerry Paul
Paul & Joan Rubschiager Foundation
Paul and Beryl Greetin Foundation
The Paul E. Singer Foundation
Peck Madigan, Jones, Inc.
Pegasus Builders
Penn Color
Peoples Health Network
Peoples Health Network
People’s United Bank
Nacho Perez
Northwest Mutual
Northwestern Mutual Foundation
Northwestern Mutual Financial Network
North Western Health
NorthwestHealth
Norton Healthcare
Norton Rose Fulbright US LLP
Nova Construction Services LLC
Novant Health
NVIDIA
Jerome Oakley
O&H, Inc.
OCDM, Inc.
Ocdm, Inc.
Odin, Feldman & Pittleman P.C.
OHC
OK Reality
O’Malley & Myers LLP
The Omer Foundation
Brian O’Neill
Orange Theory Fitness
Oregon Oncology Specialists
Ostroff Associates
Lori and John Overbeck
Pabco Construction Corp.
Pacific Service Credit Union
Dan Paolini
Papa John’s of Iowa
Paquette & Co.
PAP Electrical Contractors, Inc.
Eric Parks
Parkview Cancer Institute
Parkview Ortho Hospital
Parkview Physicians Group
Patch Painters and Allied Trades for Children’s PathGroup
Edward Patterson and Krista Coppola Patterson
Jerry Paul
Paul & Joan Rubschiager Foundation
Paul and Beryl Greetin Foundation
The Paul E. Singer Foundation
Peck Madigan, Jones, Inc.
Pegasus Builders
Penn Color
Peoples Health Network
Peoples Health Network
People’s United Bank
Nacho Perez
Northwest Mutual
Northwestern Mutual Foundation
Northwestern Mutual Financial Network
North Western Health
NorthwestHealth
Norton Healthcare
Norton Rose Fulbright US LLP
Nova Construction Services LLC
Novant Health
NVIDIA
Jerome Oakley
O&H, Inc.
OCDM, Inc.
Ocdm, Inc.
Odin, Feldman & Pittleman P.C.
OHC
OK Reality
O’Malley & Myers LLP
The Omer Foundation
Brian O’Neill
Orange Theory Fitness
Oregon Oncology Specialists
Ostroff Associates
Lori and John Overbeck
Pabco Construction Corp.
Pacific Service Credit Union
Dan Paolini
Papa John’s of Iowa
Paquette & Co.
PAP Electrical Contractors, Inc.
PEP Promotions
Pepco Holding, Inc.
PepsiCo
The Perfect Light
Performance Automotive Network
Performance Food Group, Inc.
Whitney and Scott Perkins
Maria Persky and Craig Heberton
Susan and Ronnie Pertnoy
Tracy Peters
PFG/Vistar
PGA Tour Superstore
Jennifer Philippi
The Phyllis M. Coors Foundation
Andrea Pines
The Pinkerton Foundation
PITT OHIO
Pizza Hut of America, Inc.
PNC Bank
PNC Financial Services Group
PNC Foundation
Eileen and Gerald Poblocki
Point B
Poli Bros. Foundation
Polo Ralph Lauren Foundation
Carolyn Pomroy
Fredrick and Cherie Pond
Jerry and Nadine Popham
Porsche of Melbourne
Porsche of New Orleans
Port Tampa Bay
Powell Industries
Precision Manufacturing Company Inc.
Precision Wall Tech
Premier Companies
Monika and John Preston
Douglas Prince
Principal Charity Classic
PrinterLogic
Priority Physicians
ProMedica
Prometheus Partners
Publicis Health Media/Digitas Health
The Pumping Station Inc.
PwC St. Louis
Rafael Pharmaceuticals, Inc.
Sallie Rainer
Rambus
Derek Ramsey
Marvelyn Randall
The Randy and Deborah Daniel Family Charitable Foundation
Barbara Rapaport
Robin Rawald
Real Estate Development Services
Real Estate One Foundation
Red Clay Consulting, Inc.
Red River Technology
Red Rocks Church
David Redmond
Jason and Heather Redpath
Reece Holbrook Win Anyway Foundation Inc.
Alison Reed
Regional Cancer Care Associates
Rendina Healthcare Real Estate
Shelby Reneski
James Resnick
The Rhoda and David Chase Family Foundation, Inc.
The Rhode Island Foundation
Ride for Dads
Richard M. Schulze Family Foundation
Rifenburg Construction Inc.
The Robert Black Charitable Foundation
The Robert R Sprague Foundation
Roberts Oxygen Company, Inc.
Ruth Robinson
William Robinson
Kristie Robles
Gene Rochlin
Rockefeller Group
The Rockport Group
Rock Mountain Cancer Centers
The Roderick Seward, Flossie Radcliffe and Helen M. Galloway Foundation, Inc.
Courtney and Kit Rodgers
Roeslein & Associates
The Rogers Family Foundation
Ropes & Gray LLP
Robert Rothman
Roy A. Hunt Foundation
Royal DSM
RSM
Ellen and Steve Rubesin
Richard Ruby
Margaret Rummel
Ruoff Home Mortgage
Chris Russell
S L Green Management LLC
S&P Global
Catherine and Jeffrey Sachs
Safeway, Inc.
St. Louis Blues Hockey Club, L.P.
Salinas Valley Memorial Healthcare System
San Diego County – District 3
San Diego Sign Company
San Francisco Yacht Club
San Manuel Band of Mission Indians
San Par Golf Tournament
Sandoz, Inc. PA
Sandpiper Fund, Inc.
Sanofi Genzyme
SAP National Security Services
Pamela and Bobby Sasser
John and Lori Sasso
John Saunders
Lisa and Mark Saur
Savannah Chatham Imaging
Lorne Scharberg
Mark Schambberg
The Schaufeld Family Foundation
Scheid Family Wines
Laura Schlegel
Bryan Schmidt
Marc Schneider
Sandra and Brian Schneider
Jeff Schoepfel
Schor-Lieberman Family Foundation
Scottlaw Brewing Co.
Helena and Stormy Scott
SDS Restaurant Group LLC
Sea Fox Boat Company, Inc.
The Segal Company (Midwest)
Dora Seiffer
Mark Seltzer
Sempra Employee Giving Network
Serrano Associates LLC
Sewell
The Shack
Anish Shah
Parin and Mona Shah
C. Kevin Shanahan
Dan Shapiro
Diane and Bill Shaw
Shepard 5 Points Family Foundation
Shire – MA
Kent Shoemaker
The Shooshan Foundation
Shumaker, Loop & Kendrick, LLP
R.L. Sias
Bart and Linda Sichel
The Sidney, Milton and Leoma Simon Foundation
Simmonds Family Foundation
Lauren and Robert Simmons
Bill and Carin Simpson
The Singer Family Fund
Sinkula Investments, LTD – Wendy’s
Sitemap Kids
Skoloff & Wolfe, PC
Charlie and Meg Slater
SLC Group Holdings
Sleep Family
Angie and Steve Smith
Kristie Smith
William Smith
Smith Pachter McWhorler, PLC
Steven Snodgrass, MD, FACS
Camilla and Shahan Sohigian
Meghan Somers
Southern Glazer’s Wine & Spirits
Southern Rivers Energy Trust, Inc.
Southwest ToyotaLift
Southwestern Ohio Wendy’s
Advertising Group
William Speakman
Tishman Speyer
Stephen and Bonnie Spiegel
Spire, Inc.
Splunk Inc.
Justine and David Springberg
Springs Fire Department
Shannon Stafford
St. David’s HealthCare
Gretchen Stangier
Star Anesthesia, PA
Barb and Tom Stayton
SteelFab SC
Stella International
Steve Giacin
Steward Family Foundation
Steward Health Care
Stone Bank
ANNUAL REPORT 2018
SECTION 7: ACKNOWLEDGMENTS

Vanessa and Matthew Stoyka
Strategic Property Partners
Strategic Resources International
Strayer University
Lacey and Huston Street
Suzanne Strothkamp
Brett Stuart
Subaru of Gainesville
SugarCreek
Patrick and Pam Sullivan
Peace Sullivan
Summit Funding, Inc.
Sun Trust Banks, Inc.
The SunTrust Foundation
SuperValu Inc.
Rocco and Debbie Surace
Sutter Health
Suvoda
Shirley Sutton
SWBC
Douglas Swortwood
Sykes Enterprises Inc.
Sysco Atlanta, LLC
Sysmex America, Inc.
Jack and Barbara Tarditi
TAS Foundation
Mark Taylor
TCC Gives, Inc.
Team Annie Rose Foundation
Team Dan the Man
Team Ethan, Max and Rachel’s Army
Team India
The Tecumseh Foundation
Tee Off Against Corp.
Monica Ten-Kate
Lee Tepper and Dorine Real
Terakeet LLC
Texas AirSystems, LLC
Texas Capital Bank
Texas Instruments, Inc.
Texas Oncology, P.A.
Henry Thierry
Zach Thomas
Thomas and Agnes Carvel Foundation
Thompson & Knight Foundation
Thompson, Habib & Denison, Inc.
Elizabeth Thornton Troy
Denise Thrower
Thunderbirds Charities
TIAA Charitable Inc.

Tilden-Coil Cares, Inc.
Sidney Ann Tiler
Kathryn and John Tillman
Tire Kingdom, a TBC Corporation
Company
Tito’s Handmade Vodka
TMX Finance
Johanna Tollas
Tom & Virginia Jennaro Family
Foundation, Inc.
Tooley Oil Company
Lisa Torrell and Mark Finerman
Daniel Towriss
Toyota Dealer Match Program
Ken Trainer
Transwestern Commercial
Services, LLC
Travel Resorts of North Carolina, LLC
Trend Capital Management, LP
Triangle Oktoberfest Rotary
Foundation
Trident Maritime Systems
Truenorth Energy
TSYS
Dr. Kevin and Kris Tu
Raj Paul Tuli
Turner Construction Company
Turner Foundations, Inc.
UK Healthcare-Markey
Cancer Center
US Bank
U.S. Chamber Foundation
U.S. Coffee
UST Global Inc.
U.S. Trust, Bank of America Private
Wealth Management
UAW Brownstown
UCSD/Sharp BMT Program
Mindy and Kirk Uhlaub
The Ultimate Software Group, Inc.
Unanet
Union Bank of California
United HealthCare Svs, Inc.
United Way of Central New Mexico
The University of Chicago
The UPS Foundation
Uptime Solutions
Beth and Nathan Vaisman
Richard Vanbergen
Venari Resources LLC
ViaSat
Vida Global Foundation Inc.
Vidars/LPI
Brad Vick
Lois Vick
Volkert, Inc.
The W. J. Barney Foundation Inc.
The W. O’Neil Foundation, Inc.
Lina and Christian Waage
Wachtell, Lipton, Rosen & Katz
Katherine Wagman-Cook
Walmart
The Walt Disney Company
Walt Disney Company Foundation
The Warburg Pincus Foundation
Warrenhoven Family Foundation
Washingtonian
Washington Gas
Washington Redskins
Waterford Bank
Wawanesa Insurance
Waxman Strategies
WB Engineers+Consultants/Gensler
WDG Architectural
Wedell Family Foundation
Visse Wedell
Weeks & Irvine, LLC
Weil Cornell Medicine
David Weinstein, MD
Joshua Weintraub
Marc and Shari Weissbach
Robyne Welde
David Welland
WellDyneRx
WellMed Medical Group
Welton Investment Partners
Wendy Products – Wendy’s
Marvin Wengar
Western Digital Corporation
Western Refining
Rod Westmoreland
Westcon Comstor
Wilkes & McHugh
Sara Dawn Wilkins
Julia Wilkinson
Wilco Construction Company
Thomas Williams
Williams & Connolly LLP
Willis Tower Watson
Patricia Willson
Wisenbaker Builder Services
Felix Wong
Woodforest National Bank
Woodland Auto Supply

World Wide Technology
Holding Co., Inc.
World Wide Technology, Inc.
Yoder Industries, LLC
Shunshiro Yoshimi
Young Hearts, Inc.
David Yurman
Zegar Family Fund
Joseph Zehr
Scott and Cathy Zeilinger
Zenith Insurance Company
Ziegler Bolt & Nut Co.
Zoch Children’s Foundation
Zurich American Insurance
Company
Joseph Zvesper
Anonymous (13 donors)

Top Campaign Fundraisers

The 3 Amigos
Monique Abed
Brandon Abernathy
Jen Adair
Evelyn Akers
Rachel Alkobey
Ali For A-Town
Peter Allen
Kris Allen
Sandy Allen-Bard
Luke Almendarez
The Amadeus North America Team
Nicole Ameduri Gonul
Tamara Amini
Cori Amsellem
Dr. Aimee Anderson
Jenny Anderson
Ines Andres
Walter Andrews
Michael M. Appelbaum
Lexi Arnold and Team Champions
for a Cure
The ART of Finding a Cure
Ross Ashby, Jake Hale, and
Watson Kimel
Virginia Asher
Traci Aucoin
Bryan Austin
Eduardo Balbis
Olivia Baldwin and Tessa Martinez
Hannah Baltimore
SECTION 7: ACKNOWLEDGMENTS

Bank of America Merrill Lynch
Banking on a Cure
Tamar Barbash
Barclays
Tedd Barr and Team Raising
The Barr
Davis Bass
Be The Change in honor of
Liz Lofurno
Amy Beachy
Linda Becker
Hannah Been
Chris Belone
Marlin Bernabe
Luke and Meg Bernstein
Jesse Bieretz
Libby Bish
Dana Bishop
Thea Bitar
Blackstone
Lauren Blanchard
Kylie Blank and Charlie Hirsch
Mary Blankenship Pointer
Susan Blaska
Bloomberg
Brad Blumenfeld
BMC Atlanta
BMC Austin
Josie Boehm
Jamie Bol
Eric Braate
Melvin Bradley
Carolyn Braffman
Craig T. Brasdovich
Cameron Breed
Abby Breyfogle
Katie Briscoe
JD Brooks
Ansley Brown
Mindy Brown
Jared Bruss & #survivorgoaLLS
John Buckley Jr.
Kathy Bunce-Cooper
Adam Burck
June Burke
Timothy Burke
Kate Burke
Ashley Bunch
Heather Butler
John Buxton
Darin Byer
Richard Bynum
Caleb’s Cause
The Caleb Pearson Team
Dianne Callahan
Bonnie Campagnuolo
Shelly Campbell
Keely Campbell
Cancer Crusaders
Cancer Crushers
Cancer Warriors
Robert “Spider” Cantley
Jim Carman
Kelsey Carr
Amy Carr
Louis Carrera
Stephanie Carroll
Bill Carteaux
Carter’s/OshKosh B’gosh
Jim Carty
Nikki Carver
CBH Homes
Keegan Chapman
Ivy Charmatz
Rjon Charne and Team Chai
“To Life”
Cameron Chiamante
Rob Chinsky
Shar Christopher
Francesca Ciatto
Circle of Hope
Sydney Clark
Mike Clark
George Cohlma
Spencer Coker
Shannon Colamarino
Karen Cole
Kaye Cole
Kim Collison
Colton’s Army
Enn Cones
Michael Conlon
Sean Conneen
Nicole Conti
Ken Corbett
Josh Corell and Corell’s Cancer Crushers
Tania Cortas, MD
Dan Cote
Kaye Courington
Coyotes for a Cure
Amy Crockett
Mary Cushing Doherty
Patrick Dahlgren
Andrew Dale
Dancers vs. Cancers
Darcy’s Determinators Powered by Kailie’s Krew
Darin For A Cure Team
Whitney D’Attilio
The David Adams Memorial Fund
J Greg De Felice and Blood Type: Brooklyn
Carl De Groote
Joe de Lachica and Team Huck Cancer
Katherin Decker
Ashleigh Dees
Jason Dehaemers
Kelly Delaney
Delbarton School
Jason DelGrosso
Joseph Dell’Aquila
Larissa DeMarco
Joseph DeSapia
Richard Di Pietro
Jose Felix Diaz
Ron Dickerson
Robert Dickinson
Mike Diers
Grecia Dillery
Discount Tire
Belle Ditthavong
John Doerr
Chris Donahoo
Jacqueline Downer
Dream Team
Lindsay Drew
Jakob Duchesneau
Emily Dumler
Caroline Dycio
Lauren Dzierwa
Sarah Eazzetta, Audrey Mast, and Olivia Santos
Amy Edmond
Mand Edwards
Molly Egloff
Moustafa El Hariry
Endure a Cure
Charles Esten’s Team Addie
Estron
Michael Euston
Angela Evatz
Everett Fire Department
Maddie Ewers
Executive Leadership Committee - Circle of Hope
Jamie Fagan
FarmHouse Fraternity
John Fellin Jr.
John Fellin Sr.
Darrel Ferguson
Sofia Fernandez
Carrie Fetner
Vernon Fiddler
Justin Field, MD
Jonathan Fields
Fifth Third Bank
Amy Fingerhut
Jane Finley
Catherine Finn
Valerie Fiordilino Maslow
FIS
Lea Fisher
Charlie Fleury
Rebecca Foester
Sam Forrest
Pat Foy
Chad Frampton
Chris Frantz
Barbara Freedman and Team Gary
Katy Fretag
Laura French
Jonathan Gabay
Scott Gallagher
Virginia Garner
Gators Beat Blood Cancer
Gayle’s Warriors
Hillary Geffman
Dr. Brett Gemlick
Bree Gentry
Gexa Energy
Taki Gikakis
Scott Gildea
Maddie Girard
Ella Glassman
Ella Glassman
Jason Goldberg
Goldman Sachs
Elizabeth Goldstein
Gillian Goldstein and Nicole Banhidi
Gina Gondron
Dr. Joseph Gonzalez
Kali Gonzalez
Got CUREage
Cory Gourley
Vicki Grabowski
Karen Grace
In Honor of my mother (Diane Rakoff)
In Memory of AJ Barr (Lyndsay Wyman)
In Memory of Edie Neumann (Erin Grai)
In Memory of Edie Neumann (Team Smiles for Miles)
In Memory of Jack Ingram (Lyndsay Wyman)
Nick Ineck
Mark Ingrao
InvinciBill
Tim Iorlano
Alison Isaacs
Lisa Iksic
Hilary Jacobs
Henry Jacobson
Chaya Janardhan
Noah Janssen
Brian Jaramillo, President, Tilden-Coil Constructors, In Memory of Ernest and Carol Jaramillo
Ann Gail and Justin Jaschke
Jennifer Jensen
Ron Jordon
Jerry Maahs Memorial Golf Outing
Gary Jobson
Michelle Johnson Shackelford
Grace Johnston and The Brave Bloods
Jordan Jomsky
Adam Jones
Michelle Jordan
Jumping for Joy
Karie Kading Ramsey
Randi Kaefer & Team #GameChanger
Amy Kappen
Satheesh Kathula, MD, FACP
Grace Johnston and The Brave Bloods
Ann Elizabeth Kay
Ben Kazenmaier
KC TEAM HOPE
KC Team Hope Hero Fund
Mallory Keating
Jack Kelly
Kathleen Kennedy Townsend
Alexandra Kenney
Addison Kerns and Emma Loftin
Robert Ketterer
Kevin’s CUREsaders
Kindness Krew
Annie King
Kevin Kirkpatrick
Becky Kish
Jason Klein
John Klein
James Klusaritz
Jared Knetel
John Knox and Knoxie’s Knuckleheads
Cindy Kohler
Kelli Kolkmeyer
Evan Koplan
Koppers
Chris Kostanceki
Robert Kottler
Kiven, Kotler, Lieberman, Goldschmidt, Fox, Kepes and Lev
Genelle Kumpe
L-iminators
LADA Liv’s Angels
Candi Ladwig
Kent Lance
Brian Landrum
James Lau
Emalee Lavezzo, Anthony Trolio and Team Curesaders
Jim Lear
Sarah Lee and Team FamiLee
Doug Leech
Drisha Leggitt and Team #puppiesandbabies
Kaitlin Lindsey and Team Wombat
Lisa Lobach
Kate Logan
Gina Lomurno
Khaki Loughran and Jordan Shoulberg
Lucy Loveless
Janice Lowder
Julia Lucas
Amanda Lucero
Lymphomaniacs
Chris Lynn
Jennifer Lynn
MAC and Friends
Mike H. Madokoro and Team Living the Dream – A Homework
Marshall Maggio
Amanda Maggio
Doug Manchester
Becky Mancuso-Winding
Krystina Maola, Team Krystina Kicks Cancer
Reagan Markland
Lois Markovich
Chris Marsengill
Nicole Massa
Sher Mathew
Dr. Jeff Matous
Irene May-Ling Hutchins, MD
Monique McCall
Stephen McCarty
Julie McDonough
Erin McFarland
Brenna McGahan
Amanda McHenry
McKesson Specialty Health
Brenna McLaughlin
Derek McNeil
Brandon Mears
Jeremy Mehling
Tony Mehtash
Lauren Meier
Kevin Melancon
Health Melton
Alexis Merriman
Judd Messer
Mike Metz
Lance Meyerowich
Michael K. Darby Fund for Hope
Michael Milberg
Cade James Miller
Nancy Minton
Minton’s Miracles
Jessie Miranda
Allison Mitchell and Team Kathy’s Angels
Tarang Mittal
Max Mohammadi
Dr. Charles Mok
Anson Moore
John Moriarty & Associates
Stephanie Moritz
Kevin Morris
Jeff Morris
Ruth Morris
Michael Moskowitz / Michael Moskowitz Team
Anne Moss – In Honor of Bri Mangano
Danielle Moss – In Memory of Ashley Robbins
SECTION 7: ACKNOWLEDGMENTS

George Moss Jr – In Memory of Rosebud
Sabrina Mosseau
MS 51 William Alexander
Ann Myers
Jason Myers, PhD
Shahin Naghavi
NATIVE In Nashville
Laura Neandross
Krista Neugebauer
Scott and Tim Newman
Nice Life 2017
Colin Nielson
Thamia Nieto
Michelle Orovets
Jaime Orozco
Scott Oyler
Pacific Union
Aubry Padilla
Alexis Paget
PamJam
Panthers Against Cancer
Marcy Parlett
Haley and Justin Parrish
Elizabeth Parry
Laura Pastor
Shayna Patel and Lauren Stoeckel
Hyacinth Paul-Dey
Connor Payne
Jake Peacock
Nick Pedersen
Sophia Peppas
Adolfo M. Pérez and the Carnival Cruise Line's Team
Person to Person
Jill Petruzzi
Grace Petty
Chris Pietrucci
Shane Polk
Heath Ponder
Beth Pope - Team Pope for Hope
P. Grant Portier
Stuart Powell
PS 253
Sara Radigan
Sallie Rainer

Pankaj Ramani
Rampart High School
The Red Elephants
Hannah Macy Reynolds – Straight Outta Chemotherapy
Mark Richards
Lisa Richart-Hernandez
Marcie Riches, MD, MS
Ride for Dads
Ride-4-Ron
Riders Riders of the Storm
River Oaks Elementary School – HISD
Jenna Rizik
Ryan Rizzo
Adam Roach
Derek K. Robbins / Team Frampton
August Robertson
Curt Rocca
Derick J. Rodgers
Julie Rogers
Ryan Rogers
Carla Romero
Sandra Rose
Lauren Rosenberg and The Marvelous Mensches
J. Scott Ross
Gary Rossi
Roswell High School
Casey Roszko
Jola Rothman
Mia Rothman
Brittany Rouse
Running4Lunniing
Mackenzie Ruoff
Luke Rutherford
Margie Rutenberg
Sally Ryan
Niki Salt
Harvey and Yetta Saltzman
Felicia Saracetti
Sherrin Schaffroth
Charlie Schlatter
The Schlatter Family
Marissa Schneider
Barry Schoch
Vicki and Rick Schuerger
Vicki Schuerger/ L&R Structural Corp.
Schuyler-Colfax Middle School
Martin Schweitzer
Helena Scott
Kennehra Searcy
Seattle Fire Department
Ryan Seely
Catherine Sellers, AGNP
Joe Seppa
Chuck Sevola
Michelle Shackleford
Dr. Parin Shah
Sheila Shah
Samir and Saar Shah
C. Kevin Shannahan
Ben Shapiro
Clara and Hasie Sherman
John Shumate
Chris Sigmund
Brennae Simplot
Jordyn Simpson
Alexandra Singer
Joey Slay
Matt Smith
Katie Smith
Kristie Smith
Taylor Smith and Team A Shoulder to Lean On
Tim Smith
Serena Smith, Team FIS
Nicole and Gary Snyder
Dr. Oludapo Soremi
Tony Sorrentino
Southern California Gas Company
Teresa Spittle
Kirin Sran
St. Anthony's Reunion Tour
Dr. Christian Stalwart
Silve Stankova
Delbert Stapp and Team 'Stapp Out Cancer'
Stater Bros. Markets
Katie Stephan
Jane Stein
Donald Steiner
Margaret and Donald Steiner
Kate Stevens
Shen Stewart
Stratford School Fremont
Scott Strootz
Deirdre Strunk
Hope Stuart
Patrick Sullivan
Kelly Superak
Bishoy Tadros
Meredith Tannehill
Susie Tapley
Jordan Tattersall
Danielle Tauber
Geneelle Taylor Kumpe
Team #LillyStrong
Team #Rally4Ryan..."ALL"in!
Team #Weeks Beats Cancer
Team 1 In A Million
Team Alaska Airlines
Team Amy
Team b.strong
Team Bad Blood
Team Bank of America
Team Believe
Team Big Harts
Team Bloomberg
Team Blumenfeld-Waterman
Team Booyah!
Team Bug Eye
Team Cancer Crusaders
Team Chem-NO-therapy – Kaci Stewart and Katie Wong
Team Clan Fraser
Team Close Cares
Team Crushin' Orange
Team Drive
Team Ecks Factor
Team Fly4aCure
Team Frampton
Team Fulton
Team Gators Beat Blood Cancer
Team Gene
Team Good Addie-tudes
Team Good Hands Warriors
Team Got CUReage
Team Guillottas Fight Cancer and GIO Strong
Team Guy Harvey
Team Hardesty
Team Hearts of Gold
Team Heinz
Team Help Is In Our Blood – Gabby Brutman, Leah Padden and Wynn Dietzler
Team Homoky
Team Hope & Love
Team Husky
Team In Honor of Beth Scheibl
Team John Henry
Team Kim
Team Kinzie
Team KPMG
Team LCR
Team LG Peeps
Team LLS North Carolina
Team LOL
Team NARS
Team Notable Labs – Pete Quinzio
Team Pammy
Team Parkettes
Team Paul
Team Phoenix
Team Ram
Team ROE
Team S.W.A.T.
Team Straight Outta Chemo
Team Survivor
Team Sweet T
Team Tartan
Team Thomas
Team Triumvirate
Team Unstoppable, Stacy Schneeweis and Diane Paradise
Team V
Team Wendy’s
Team Yahoo!
Team Yankee
Team Zephyr
Britanee TeBrake

Terumo BCT
Jason Thomas
Zach Thomas
Pam Thomas-Grieshop and LLS Team for Life
Robbie Tindall
Alex To, Emma Peters and Team Just Cure It!
Kevin Tolbert
Sidney D. Torres IV
Bridget Toscano
Tom Treinen
Triple Threat
Ansley Tripp
Gary Trovato
Danielle Turcot
UCLA Health
Gregory R. Unatin
Valley Forge Middle School
Clare Vanderbeek and Jack Morkian
Venture First
Kristy Voytek
Waconia Middle School
Shannon Walker
Tamra Wallerstein and Team Curing Cancer with Kindness
Walt Whitman High School
Walter Johnson High School
Freda Wang
Kimberly Ward
Don and Angie Ward
Beth Waring
Diana Warner
Sara Warren
Washington Gas
Julie Wasserstrom
Brian Waterman
Watertown Middle School
We Will Fina A Cure
Ashley Weber
Ashley Webster
Rhonda Webster
Sydney Weinstein
Parker Welch
Madison Whitcomb
Amy Whited
William Mason High School
Elysa Williams
Matthew Williams
Richard Williams

Cole Williamson
Jeff Willman
Christopher Wino
Dwayne Wilson
Megan Wilson
Brandon Winn
World Bank Community
Randy Wirtz
Ernie Yarborough
Ravid Yosef
Young Hearts
Robert Zabber
Zac’s Pac
Matt Zamb
Erin Zammert Ruddy
Julie Zawacki
Jeremy Zeisloft
Zephyr
Jacqueline Ziemsanski
Orli Zimmerman
Zionsville Community High School

Legacy Circle

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year.

Carlette Allen*
Steve and Madeline Anbinder
Sally Arias* in memory of Reynaldo W. Arias, IV.
C. Annette Bailey*
Vincent Baudo*
Algene Bogard*
Dorothy M. Booth* Charitable Trust, Bank of America, Co-trustee
Nancy Burgett in honor of David Ray Joseph G. Cesario in memory of Gregg Cesario
Craig Clark
David Davis*
Marian Maxine Davis*
Charlene Dean*
Charlene Deutsch*
Nicholas Dissier*
Peggy & Margaret Dupaquier Trust*
Robert Ellis*
Judith Erickson*
James and Lynn Fager*
Suzanne Fedder*
Anita Foster*
Ann Fox*
Don Leon Fussell*
Ann Gilman*
Harvey Hall*
Barbara Hellman*
George Randall Henderson in memory of George N. Henderson
Alton Hitts*
William F. Hoffman*
Julie and Thomas Hubbard*
Oliver W. Jackson*
Lillian Jacobs*
Edward Jaramillo*
Lewis Kaplan*
Carmela and Leo Karl*
John Kellenyi**
Rosella Kenaston*
Irvin King in memory of Bertha D. King
Evelyn Kruish*
Linda Lumsden*
Roy Maas*
Cynthia Magarya*
Bernard Malberg*
Jane Marret*
Richard Mattfeld*
Catherine McCally*
Bruce Peyton McDonald in memory of Thomas R. McDonald
Gloria Mehl*
Pam Olson
Emily Papapietro*
Mary Alice Parks*
Ronnie Pertnoy in memory of Civie and Earl Pertnoy
Tua Cleo Plant*
Edna Raupp*
Richard Rawley*
Margo Reagan*
Margaret Rendall*
Deloris Riggins* in memory of Ronald K. Brownlee, Jr.
Frank Roedell*
Patricia Rogers*
Helen Roth*
Robert Ruhe*
Bruno and Irma Selmi*
Lois Stockert*
Shirley Temme*
Robert Trusler*
Phil and Kathy Vasile
Donna Wahlen*
Abie Werth*
Thomas West*
Loren Woerner*
Catherine Woodfield*
Shirley and Hal Wright*
Anonymous (5)

* Deceased

* We proudly recognize John Kellenyi, generous, longtime supporter and Beat AML Campaign co-chair, for his leadership, compassion, and commitment.
Initiatives & Portfolios

LLS Initiatives and Portfolios are groups of research projects and patient access & advocacy programs targeted toward a specific blood cancer and/or impact area. The list below includes donors that generously invested in a specific LLS Initiative or Portfolio during this fiscal year.


Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Lisa Norcia Cheskin and Barry Cheskin.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by the Dyer Family Foundation and Lisa Norcia Cheskin and Barry Cheskin.

Chronic Lymphocytic Leukemia Portfolio is funded in part by Paul E. and Sharon Dillon, the Frances & Gertrude Levett Foundation, Christopher and Patricia Kelly, Ronald P. Reis, Ann Taylor, and anonymous.

Chronic Myelogenous Leukemia Research Portfolio is funded in part by Tom McCarthy and Leslie and Larry Nance.

The LLS Children’s Initiative & Pediatric Portfolio are funded in part by the Franklin American Mortgage Company, The Harry T. Mangurian, Jr. Foundation, Inc., the Thomas and Agnes Carvel Foundation, The Rhoda and David Chase Family Foundation, and the Wowa Foundation.

Hodgkin Lymphoma Research Portfolio is funded in part by AM Charity Fund.


Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by the Barbey Family, Doug Baughman, Timothy and Cristine Lindenfelser, Michael Maser, Lisa Norcia Cheskin and Barry Cheskin, and Jerry and Lois Rosenblum.

Information Resource Center (IRC) Portfolio is funded in part by Genentech and Pharmacies.

LLS Patient Access & Public Policy Portfolio is funded in part by The John and Frances Beck Family Foundation.

Myeloma and Waldenstrom Macroglobulinemia Portfolio is funded in part by Jana Broach, the Carlson Foundation, the Edward J. Phillips Family Foundation, and Niles Hushka.

Therapy Acceleration Portfolio is funded in part by Jerry and Lois Rosenblum.

Women in Research Portfolio is funded in part by Linda Schwartzstein.

Endowment Funds

The Bill Beattie Memorial Endowment Fund (Alberta)
de Villiers Endowment Fund
GlaxoSmithKline Foundation – Gertrude B. Elion Endowment Fund
GlaxoSmithKline, Inc. Research Fund

Jane Elissa/Charlotte Meyers Endowment Fund
Jim Jacobs Leukemia Research Fund
Mary & Robert Bronstein Memorial Fund

The Rachel Kudish Fund
The Rae Endowment Fund (Ontario)
Reich Endowment Fund
Thomas M. Ford Memorial Fund
The United Food and Commercial Workers (Canada) Endowment Fund

The Virginia Major Brooks Memorial Endowment Fund
Vrushali Ranadive Fellowship Fund

ANNUAL REPORT 2018 94
Leadership

National Board
Volunteers serve on our National Board of Directors providing leadership and governance to help find blood cancer cures.

Chairman of the Board
Peter Brock
Brock Development
Palm Beach Gardens, FL

Vice Chair
Jorge Benitez
Fort Lauderdale, FL

Secretary/Treasurer
Ralph E. Lawson, FHFMA, CPA
Baptist Health South Florida
Coral Gables, FL

At Large
Bart Sichel
Burlington Stores
Florence Township, NJ

Directors
William G. Behnke
The Behnke Group
San Antonio, TX

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Renzo Canetta, MD
Madison, CT

Elizabeth J. (Betsy) Clark, PhD
Saugerties, NY

William S. Dalton, MD, PhD
M2Gen
Tampa, FL

Bernard H. Garil
Delray Beach, FL

Francis Heller
Arabesque Asset Management
New York, NY

Joseph B. Kelley
Lilly USA, LLC
Washington, DC

Mary Kennard, JD
Bethesda, MD

Michelle LeBeau, PhD
University of Chicago
Comprehensive Cancer Center
Chicago, IL

Connie L. Lindsey
Northern Trust
Chicago, IL

Kathleen Meriwether
Ernst & Young, LLP
Philadelphia, PA

Ted Moroz
The Beer Store
Ontario, Canada

Lynne O’Brien
Washington, DC

Marla Persky, JD
WOMN LLC
Ridgefield, CT

Donald Proctor
Bk97 Digital
Walnut Creek, CA

Robert Rosen
Greyhawke Capital Advisors, LLC
Greenwich, CT

Steven T. Rosen, MD, FACP
City of Hope
Duarte, CA

Jeff Sachs
Jones Lang LaSalle
Atlanta, GA

Kenneth Schwartz
Ernst & Young, LLP
New York, NY

Frank O. Smith, III, MD
Medpace
Cincinnati, OH

Keith S. White
ParkerWhite Brand Interactive
Cardiff by the Sea, CA

Executive Leadership

The Leukemia & Lymphoma Society

Louis J. DeGennaro, PhD
President & Chief Executive Officer

Robert Beck
Executive Vice President
Chief Operating Officer

Andrew S. Coccari
Executive Vice President
Chief Product Officer

Danielle Gee
Chief of Staff

Kathy Griesenbeck
Interim Executive Vice President
Chief Relationship Officer

Marcie Klein
Executive Vice President
Chief Communications Officer

Rosemarie Loffredo
Executive Vice President
Chief Financial Officer

Gwen Nichols, MD
Executive Vice President
Chief Medical Officer

Tom Osgood
Executive Vice President
Chief Human Resources Officer

Alice Rodd O’Rourke
Executive Vice President
Chief Development Officer

The Leukemia & Lymphoma Society of Canada

Alicia Talarico
President
Canadian Operations

Offices

United States:
https://www.lls.org/
chapter-selection-page

Canada:
http://www.llscanada.org/
chapter-selection-page
The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.